Delirium · Web of Medicine

On this page

Quick Reference

RxDrug of choice[[Dexmedetomidine]] (prevention in ICU); [[Haloperidol]] (symptom control for severe agitation)

AltAlternatives[[Ramelteon]] (prevention); [[Quetiapine]] or [[Olanzapine]] (off-label symptom management)

⊘Avoid[[Rivastigmine]] (in ICU delirium); [[Benzodiazepines]] (unless withdrawal-related)

DxTest of choice[[Confusion Assessment Method]] (CAM) or CAM-ICU

ScKey scorePAWSS (for alcohol withdrawal risk); RASS (for agitation/sedation depth)

→When to referRefer to Geriatrics or Psychiatry for persistent delirium, suspected underlying dementia, or refractory agitation.

Delirium is a medical emergency of the brain; management requires treating the underlying cause and using non-pharmacological environmental support as the primary therapy.

Delirium is an acute, fluctuating neurocognitive syndrome characterized by disturbances in attention, awareness, and cognition. It represents a medical emergency of the brain, often serving as the first clinical sign of systemic illness, drug toxicity, or metabolic derangement. Affecting up to 20% of general hospital patients and over 75% of those in the ICU, delirium is a potent driver of adverse outcomes, including a 12-fold increased risk of future dementia and nearly double the long-term mortality rate. The condition is classified into hyperactive, hypoactive, and mixed phenotypes; the hypoactive variant is the most common and most frequently missed, yet it carries the poorest prognosis. Management focuses on identifying and reversing underlying triggers while utilizing non-pharmacological environmental interventions as the primary therapeutic foundation.

Overview and Recommendations

Background

•Delirium is a transient neurocognitive impairment that develops over hours to days and typically fluctuates in severity throughout the day, often worsening at night (sundowning). It is classified by psychomotor activity into hyperactive (agitation, restlessness), hypoactive (lethargy, stupor), and mixed phenotypes.
•The 'vulnerability-precipitant' model explains its occurrence: patients with low baseline reserve (e.g., , , or age >85) may develop delirium from minor insults like a UTI, while healthy individuals require major physiological stressors like sepsis or cardiac surgery.
•Neurobiological drivers include a central cholinergic failure (acetylcholine depletion) and reciprocal dopaminergic excess, alongside neuroinflammation where systemic cytokines compromise the blood-brain barrier and activate neurotoxic microglia.
•Epidemiological stakes are high, with a point prevalence of ~18% in general wards and up to 76% in mechanically ventilated patients; notably, an episode of delirium increases the odds of a new dementia diagnosis by 12.52 times over four years.
•Landmark trials like MIND-USA and AID-ICU have shifted the paradigm away from routine antipsychotic use, demonstrating that does not reduce delirium duration or mortality in the general ICU population.

Evaluation

•Suspect delirium in any patient with an acute change in mental status, especially those with fluctuating levels of consciousness, inattention, or disorganized thinking.
•Screen for inattention using bedside tests such as the Digit Span (reciting numbers backward) or the Vigilance 'A' test (tapping for the letter 'A' in a random string); inability to maintain focus is the clinical hallmark.
•Apply the (CAM) as the gold-standard bedside tool (LR+ 9.6); for ICU or mechanically ventilated patients, use the CAM-ICU to assess for acute onset, fluctuation, and inattention.
•Examine for the hypoactive phenotype, characterized by slowed speech, apathy, and reduced motor activity, which is frequently misdiagnosed as or simple fatigue.
•Order a comprehensive metabolic panel, CBC, and urinalysis to identify common precipitants like electrolyte imbalances, infection, or renal failure; check (CRP) as a marker of neuroinflammatory risk.
•Review the medication list for deliriogenic agents, specifically focusing on , anticholinergics (e.g., diphenhydramine), and high-dose (which carry a 5.14 HR for confusion).
•Assess for alcohol withdrawal using the PAWSS score; a score ≥4 indicates a high risk for , while a history of prior withdrawal seizures (LR 2.9) should prompt aggressive monitoring.
•Order an ECG to establish a baseline QTc interval before considering antipsychotics, as IV is associated with Torsades de Pointes, particularly when the QTc exceeds 450-500 ms.
•Consider neuroimaging (CT/MRI) only if there are focal neurological deficits, a history of recent head trauma, or if the delirium remains unexplained after a thorough medical workup.
•Differentiate from by the speed of onset (days vs. years) and the level of consciousness (fluctuating in delirium vs. alert in early dementia).

Management

•Prioritize non-pharmacological multicomponent interventions as first-line therapy: ensure day-night orientation, provide visual/hearing aids, promote early mobilization, and cluster care to allow for undisturbed sleep.
•Initiate pharmacological prophylaxis with low-dose 0.1 μg/kg/hr in high-risk postoperative ICU patients to reduce delirium incidence (NNT = 8).
•Avoid (e.g., ) for general delirium as they often exacerbate cognitive dysfunction, except in cases of or withdrawal.
•Reserve for severe agitation that threatens patient safety or essential medical equipment; administer 0.5 mg to 2.0 mg (IV or IM) and monitor for extrapyramidal symptoms.
•Administer 3 mg IV in combination with 2 mg IV specifically for agitated delirium in palliative care settings to achieve more rapid symptom control.
•Utilize melatonin agonists like 8 mg at bedtime for elderly patients in acute care to reduce the risk of incident delirium (OR 0.07).
•Monitor cardiac rhythm via telemetry if the cumulative dose of IV reaches 100 mg or if the QTc interval exceeds 500 ms to prevent fatal arrhythmias.
•Discontinue any antipsychotics initiated during the hospital stay as soon as symptoms resolve; continuation post-discharge is associated with increased mortality (HR 0.77).
•Implement a 'no sedation' or 'light sedation' protocol (targeting RASS 0 to -1) for mechanically ventilated patients to shorten delirium duration and ventilator days.
•Avoid and other cholinesterase inhibitors for the treatment of delirium, as they have been associated with increased mortality in ICU settings.
•Refer for physical and occupational therapy immediately; early mobilization combined with sedation interruption can halve the duration of delirium from 4 days to 2 days.
•Manage terminal delirium in the dying patient by prioritizing comfort; recognize that artificial hydration may sometimes increase respiratory secretions and agitation.

Board Review — High Yield

•Hypoactive Delirium, The most common phenotype, frequently missed, and carries a worse prognosis than hyperactive delirium.
•Inattention, The clinical hallmark of delirium; tested via digit span or reciting months of the year backward.
•Cholinergic Failure, The primary neurotransmitter hypothesis explaining the cognitive fluctuations in delirium.
•CAM-ICU, The validated tool for diagnosing delirium in non-verbal, mechanically ventilated patients.
•Benzodiazepines, Generally avoided in delirium as they are independent risk factors for worsening the condition, except in alcohol/GABA-agonist withdrawal.
•Haloperidol Safety, Requires ECG monitoring for QTc prolongation; telemetry is mandatory if cumulative IV dose >100 mg.
•Dementia Risk, A single episode of delirium is associated with a 12-fold increased risk of future dementia diagnosis.
•Dexmedetomidine, An alpha-2 agonist that reduces delirium incidence in the ICU compared to benzodiazepines (NNT = 8).

Deep Dive — Evidence Details

Definition, Classification and Nomenclature

▸Delirium is defined by acute fluctuations in attention and awareness, typically developing over hours to days.
▸The syndrome is classified into hyperactive, hypoactive, and mixed phenotypes based on psychomotor activity.
▸Postoperative delirium (POD) is a distinct acute event occurring within 7 days of surgery, whereas postoperative cognitive dysfunction (POCD) is a more persistent, subtle impairment.

HY High Yield: The Confusion Assessment Method (CAM) is the most validated bedside instrument for diagnosis, with a summary-positive likelihood ratio of 9.6 (95% CI, 5.8-16.0) [5].

Delirium is an acute, fluctuating clinical syndrome characterized by a disturbance in attention, awareness, and cognition ^[7]^A1a. It represents a transient neurocognitive impairment that typically develops over a short period, hours to a few days, and tends to fluctuate in severity throughout the day ^[4]^A1a. The condition is a significant driver of adverse outcomes, including increased mortality, prolonged hospital stay, and a higher risk of incident dementia ^[4]^A1a^[5]^A1a.

Synonyms and Nomenclature

Clinicians encounter various terms for delirium depending on the setting and historical context. Common synonyms and abbreviations include:

Acute Confusional State
Acute Brain Failure
Encephalopathy (often qualified as metabolic, toxic, or septic)
ICU Psychosis or ICU Delirium ^[7]^A1a
Postoperative Delirium (POD) ^[4]^A1a
Sundowning (referring to evening-time symptom exacerbation)

Diagnostic Taxonomy and Classification

Delirium is classified within the DSM-5-TR and ICD-11 as a neurocognitive disorder. It is primarily categorized by its psychomotor activity levels, which dictate the clinical presentation and often the ease of detection ^[3]^D5.

Phenotype	Key Distinguishing Feature	Clinical Presentation
Hyperactive	Increased psychomotor activity	Agitation, restlessness, and potential combativeness ^[3]^D5.
Hypoactive	Decreased psychomotor activity	Stupor, lethargy, and reduced awareness; often underdiagnosed ^[3]^D5^[6]^A1a.
Mixed	Fluctuating activity levels	Alternating features of both hyperactive and hypoactive states.

Related Neurocognitive Constructs

It is critical to distinguish delirium from other postoperative or chronic cognitive states to ensure appropriate ^[4]^A1a.

Postoperative Delirium (POD): An acute disturbance occurring up to 7 days after surgery ^[4]^A1a.
Postoperative Cognitive Dysfunction (POCD): A more subtle, persistent impairment involving memory and intellectual deficits that may last weeks or months ^[4]^A1a^[9]^A1a.
: A psychomotor syndrome that may overlap with delirium but is characterized by pathognomonic features like waxy flexibility or verbigeration ^[3]^D5.

Pearl: Delirium is a medical emergency of the brain; the hypoactive variant is the most common and most frequently missed, yet it carries a prognosis as poor as or worse than the hyperactive form ^[5]^A1a^[6]^A1a.

Clinical Phenotypes of Delirium

Phenotype	Key Distinguishing Feature	Clinical Presentation
Hyperactive	Increased psychomotor activity	Agitation, restlessness, and potential combativeness ^[3]^D5.
Hypoactive	Decreased psychomotor activity	Stupor, lethargy, and reduced awareness; often underdiagnosed ^[3]^D5^[6]^A1a.
Mixed	Fluctuating activity levels	Alternating features of both hyperactive and hypoactive states.

Neurobiology and Pathophysiology

▸Delirium arises from a 'vulnerability-precipitant' interaction, where baseline frailty or cognitive impairment lowers the threshold for acute triggers.
▸The core neurochemical mechanism involves a relative deficiency in acetylcholine and a functional excess of dopamine.
▸Neuroinflammation, driven by microglial activation and blood-brain barrier disruption, links systemic illness (sepsis, surgery) to acute brain dysfunction.

HY High Yield: The 'cholinergic hypothesis' explains why drugs with high anticholinergic burden (JARS score ≥3) are potent precipitants of delirium, especially in patients with preserved baseline cognition (MMSE ≥24) [50].

The transition from baseline cognitive stability to acute delirium is driven by a complex interplay between pre-existing brain vulnerability and acute physiological precipitants ^[28]^D5. This mechanism is best understood through the 'vulnerability-precipitant' model, where patients with low baseline reserve (e.g., those with , , or preoperative depression) require only minor insults to trigger a clinical episode ^[28]^D5^[41]^B2a^[47]^D5.

Neurotransmitter Imbalance and Cholinergic Failure

A central tenet of delirium pathogenesis is the disruption of cholinergic neurotransmission ^[24]^A1b^[31]^A1a. Acetylcholine is critical for attention and arousal; its depletion or blockade is a primary driver of cognitive fluctuation ^[44]^D5.

Dopaminergic Excess: Reciprocal increases in dopamine activity often accompany cholinergic failure, contributing to the hyperactive phenotype ^[29]^B3b.
GABAergic Dysregulation: Both excessive GABAergic activity (e.g., from ) and acute withdrawal from GABA receptor agonists (e.g., , ) can precipitate delirium ^[32]^A1a^[42]^C4^[53]^B3b.

Neuroinflammation and the Glial Response

Systemic insults, such as sepsis or major surgery, trigger a neuroinflammatory cascade mediated by the blood-brain barrier (BBB) and glial cells ^[39]^D5^[55]^D5.

Peripheral Cytokine Release: Systemic inflammation (e.g., via the lung-brain axis during mechanical ventilation) releases pro-inflammatory cytokines that increase BBB permeability ^[54]^D5^[55]^D5.
Microglial Activation: Once the BBB is compromised, microglia transition to a reactive state ^[39]^D5. In the absence of normal cholinergic inhibition, these cells may become neurotoxic, driving a self-propelling inflammatory reaction ^[44]^D5.
Astrocyte Dysfunction: Impaired astrocytes contribute to aberrant brain energy metabolism and glymphatic system failure, hindering the clearance of metabolic waste and neurotoxins ^[39]^D5.

Neural Network Connectivity

Functional MRI studies during delirium episodes reveal a breakdown in the normal architecture of brain networks ^[29]^B3b.

Disrupted Reciprocity: There is a loss of the normal inverse correlation between the dorsolateral prefrontal cortex (DLPFC) and the posterior cingulate cortex (PCC) ^[29]^B3b.
Subcortical Connectivity: Functional connectivity within the intralaminar thalamic and caudate nuclei is reduced during delirium but recovers upon resolution ^[29]^B3b.
Cerebral Autoregulation: Deviations in mean arterial pressure (MAP) below an individual's lower limit of autoregulation may exacerbate brain injury and delirium risk, particularly in cardiac surgery ^[52]^B2b.

Pathogenic Mediators and Pathways

Pathway	Mechanism	Clinical Impact
Orexin System	Dual orexin receptor antagonists (DORAs) like or regulate sleep-wake cycles ^[43]^A1a^[53]^B3b.	Reduced delirium risk compared to GABAA agonists (RR 0.13) ^[53]^B3b.
Glutamatergic	Dysfunction in glutamate signaling is implicated in both delirium and comorbid depression ^[12]^A1a.	Potential target for future NMDA-modulating therapies ^[12]^A1a.
Neuromuscular	Reversal agents like may reduce POD compared to (RR 0.67) ^[49]^A1a.	Avoids the anticholinergic co-administration required with neostigmine ^[49]^A1a.

Pearl: Delirium is not a single-receptor disease but a network-level failure where neuroinflammation and cholinergic deficiency converge on a vulnerable brain ^[28]^D5^[44]^D5.

Neurobiological Drivers of Delirium

Mechanism	Key Mediators	Pathophysiological Result
Cholinergic Failure	Acetylcholine	Impaired attention, fragmented sleep, and cognitive fluctuation.
Neuroinflammation	Cytokines, Microglia	BBB breakdown, oxidative stress, and bioenergetic failure.
Network Disruption	DLPFC, PCC, Thalamus	Loss of functional connectivity and impaired integration of sensory input.
Metabolic Stress	Glucose, Lactate	Astrocyte dysfunction and glymphatic clearance failure.

Epidemiology, Etiology and Risk Factors

▸Delirium prevalence varies by acuity, from 18% in general wards to over 75% in specific ICU populations.
▸Systemic inflammation and iatrogenic exposures, particularly glucocorticoids (HR 5.14) and specific antibiotics, are potent precipitating factors.
▸Subsyndromal delirium is a high-risk state, with nearly 50% of cases progressing to full syndromal delirium.

HY High Yield: The Prediction of Alcohol Withdrawal Severity Scale (PAWSS) is highly predictive of severe withdrawal delirium (delirium tremens), with an LR of 174 when ≥4 criteria are met [65].

The transition from the neurobiological vulnerability of the aging brain to clinical delirium is mediated by a complex interplay of predisposing and precipitating factors. While the point prevalence of delirium in general hospital populations is approximately 17.7% to 18.6% ^[100]^B2c, the incidence varies dramatically by clinical setting and underlying pathology. In patients with , the pooled incidence is 18.5% ^[85]^B2c, whereas in those with (ARDS), the prevalence reaches 41% (95% CI 23-58%) ^[87]^B2c.

Incidence and Demographic Distribution

Incidence is highest in surgical and intensive care settings, particularly among older adults. Following surgery, medical complications including delirium occur in 23% of patients, with a higher risk in those aged >85 years (27%) compared to those aged 65-75 years (18%) ^[94]^B2b.

General Hospitalization: Point prevalence of full syndromal delirium is 12.2% to 18.6% ^[100]^B2c.
Intensive Care: Incidence of delirium in mechanically ventilated patients ranges from 54% to 76.6% depending on the used ^[27]^A1b.
Subsyndromal Delirium (SSD): SSD is common, with a point prevalence of 7.7% to 13.2% in general wards ^[100]^B2c and up to 16.3% after cardiac surgery ^[93]^B3b. Approximately 46.3% of patients with SSD subsequently progress to full delirium ^[93]^B3b.
Demographics: Risk is consistently higher in males (OR 1.34 in some cohorts) and older age groups ^[90]^B3b^[93]^B3b^[94]^B2b.

Etiological Risk Factors

Delirium typically arises from the summation of baseline vulnerability (predisposing factors) and acute insults (precipitating factors).

Factor Category	Specific Risk Factor	Effect Size (OR/RR/HR)	Evidence Level
Baseline	History of	LR 2.9 ^[65]^A1a	1a
Baseline	Pre-existing	RR 2.2 ^[66]^A1b	1b
Baseline	Age (per year increase)	OR 1.039 ^[93]^B3b	3b
Acute Insult	Systemic Infection (e.g., )	HR 1.83-5.14 ^[73]^B2b	2b
Acute Insult	(Acute SARS/MERS)	Prevalence 27.9% ^[1]^A1a	1a
Iatrogenic	(First course)	22.2 per 100 person-years ^[72]^C4	2b
Iatrogenic	(vs )	Mean 11.9 vs 12.2 delirium-free days ^[101]^A1b	1b

Modifiable and Iatrogenic Triggers

Pharmacological agents and physiological derangements are primary modifiable levers. High-dose (>4.5 mg/day) is associated with increased extrapyramidal symptoms ^[80]^A1a, while like are associated with fewer delirium-free days compared to (3 days vs 7 days; p=0.01) ^[78]^A1a.

Physiological Derangements: Independent risk factors include postoperative stress (OR 1.848), albumin <33.4 g/L (OR 1.97), and hemoglobin <90 g/L (OR 2.284) ^[93]^B3b.
Surgical Factors: Cardiopulmonary bypass and major orthopedic procedures are high-risk; however, the choice between spinal and general anesthesia does not significantly alter delirium incidence (20.5% vs 19.7%; RR 1.04) ^[62]^A1b^[66]^A1b.

Pearl: Delirium risk is a titration of baseline frailty against acute insult; even minor triggers like or low albumin can precipitate a full syndrome in the vulnerable brain ^[93]^B3b^[101]^A1b.

Incidence of Delirium by Clinical Setting

Setting	Incidence/Prevalence	Population
General Hospital	17.7% - 18.6%	All adults ^[100]^B2c
Heart Failure	18.5%	Hospitalized ^[85]^B2c
Hip Fracture Surgery	23%	Age >65 ^[94]^B2b
ARDS	41%	ICU patients ^[87]^B2c
Mechanical Ventilation	54% - 76.6%	ICU patients ^[27]^A1b

Clinical Presentation

▸Delirium is defined by acute fluctuations in attention and awareness, often with a disrupted sleep-wake cycle.
▸The hypoactive subtype is the most prevalent (89% in some ICU cohorts) but is frequently under-recognized compared to the hyperactive subtype.
▸Inattention and impaired comprehension are the core cognitive features that best account for the syndrome.

HY High Yield: Inattention is the most sensitive clinical marker for delirium. If a patient cannot name the months of the year backward or perform a simple digit span, delirium should be suspected regardless of their level of agitation [5], [126].

Building upon the identified risk factors, delirium manifests as an acute, fluctuating disturbance in attention and awareness that typically develops over hours to days ^[28]^D5, ^[116]^D5. The clinical hallmark is a reduced ability to direct, focus, sustain, or shift attention, often accompanied by a global impairment of cognitive functions including memory, orientation, and language ^[7]^A1a, ^[28]^D5.

Presenting Symptoms

Patients typically present with a rapid change from baseline mental status, often characterized by:

Acute onset and fluctuation: Symptoms often wax and wane throughout the day, frequently worsening at night ("sundowning") ^[28]^D5.
Inattention: Difficulty following conversations, easily distracted by irrelevant stimuli, or inability to perform simple tasks like serial subtractions ^[5]^A1a, ^[126]^C4.
Disorganized thinking: Fragmented or incoherent speech, rambling conversation, and illogical flow of ideas ^[116]^D5.
Altered level of consciousness: Ranging from hyperalert and agitated to drowsy or stuporous ^[3]^D5, ^[25]^A1b.
Sleep-wake cycle disturbances: Daytime somnolence and nighttime insomnia are highly frequent ^[126]^C4.

Neurological and Psychomotor Findings

The psychomotor presentation is a primary basis for clinical classification, though neurological signs may be subtle or non-specific ^[3]^D5.

Motor Activity: May show marked agitation (picking at bedclothes, attempting to pull out IV lines) or profound retardation (slowness of movement, reduced speech) ^[25]^A1b, ^[99]^C4.
Autonomic Instability: Tachycardia, , and diaphoresis are common, particularly in hyperactive or withdrawal-related states ^[23]^A1b, ^[27]^A1b.
Psychosis: Perceptual disturbances (hallucinations, often visual) and delusions occur in approximately 20-30% of cases but are not required for diagnosis ^[126]^C4.

Phenotypic Variants

Delirium is categorized into three primary motor subtypes, which influence both recognition and prognosis ^[25]^A1b, ^[99]^C4.

Variant	Key Features	Frequency
Hypoactive	Lethargy, slowed speech, reduced motor activity, and apathy. Often misdiagnosed as depression ^[99]^C4, ^[107]^A1a.	~89% in ICU ^[25]^A1b
Hyperactive	Agitation, combativeness, hallucinations, and autonomic arousal ^[25]^A1b.	~11% in ICU ^[25]^A1b
Mixed	Fluctuating between hyperactive and hypoactive features within short periods ^[25]^A1b.	Variable

Red Flags and Atypical Presentations

Clinicians must maintain a high index of suspicion for "silent" presentations and life-threatening complications.

Functional Decline: In older adults, delirium may present solely as a functional decline or "loss of independence," which mediates 26% of dementia-associated mortality risk ^[124]^B2b.
Subsyndromal Delirium: Patients may exhibit some features (e.g., inattention) without meeting full diagnostic criteria; this state still carries a high risk of progression and poor outcomes ^[99]^C4, ^[100]^B2c.
Catatonic Features: Overlap exists between hypoactive delirium and , including stupor or waxy flexibility ^[3]^D5.
Respiratory Compromise: In mechanically ventilated patients, delirium is associated with increased ventilator-free days and higher mortality ^[108]^A1b, ^[109]^A1b.

Pearl: Hypoactive delirium is the most common phenotype (up to 89% in ICU settings) but is frequently missed because the patient is "quiet"; always screen for inattention if a patient appears unusually withdrawn or lethargic ^[25]^A1b, ^[100]^B2c.

Delirium Motor Subtypes

Subtype	Clinical Characteristics	Clinical Risk
Hypoactive	Drowsiness, decreased speed of actions, staring, and reduced responsiveness ^[99]^C4.	Highest risk of being overlooked; associated with worse prognosis ^[107]^A1a.
Hyperactive	Restlessness, agitation, rapid speech, and irritability ^[25]^A1b.	High risk of accidental injury or interference with medical care (e.g., self-extubation) ^[70]^A1b.
Mixed	Normal or fluctuating level of activity; rapid shifts between hyper- and hypo- states ^[25]^A1b.	Requires frequent reassessment to capture the full clinical picture.

Diagnosis and Workup

▸The Confusion Assessment Method (CAM) is the gold-standard bedside instrument with a positive likelihood ratio of 9.6.
▸Inattention and sleep-wake cycle disturbances are the most frequent symptoms, whereas disorientation is often less prevalent.
▸Cerebral small vessel disease and perioperative covert strokes are significant organic risk factors that increase the odds of delirium nearly three-fold.

Dx Diagnostic Essentials: The diagnosis of delirium is clinical. Use the Confusion Assessment Method (CAM) for general wards and the CAM-ICU for critically ill patients to operationalize DSM-5-TR criteria.

HY High Yield: Inattention is the 'sine qua non' of delirium. If a patient can maintain focus through a brief interview or a formal attention task (e.g., months of the year backward), the likelihood of delirium is significantly reduced.

Establishing a diagnosis of delirium requires a structured clinical assessment focused on acute changes in attention and cognition ^[28]^D5. Because delirium is often underrecognized in hospital settings, clinicians must prioritize the identification of its core features: an acute onset with a fluctuating course, inattention, and either disorganized thinking or an altered level of consciousness ^[5]^A1a^[116]^D5.

Clinical Diagnostic Criteria

The DSM-5-TR remains the gold standard for diagnosis, requiring evidence of a disturbance in attention and awareness that develops over a short period (hours to days) and represents a change from baseline ^[116]^D5^[142]^A1a.

Core Features: Inattention and sleep-wake cycle abnormalities are the most frequent phenomenological findings ^[126]^C4.
Cognitive Deficits: Disorientation is common but may be the least frequent cognitive deficit compared to inattention ^[126]^C4.
Subsyndromal Delirium: Patients may present with some but not all diagnostic features. Subsyndromal delirium is characterized by a point prevalence of approximately 25% in acute hospital populations when combined with full delirium ^[100]^B2c. Inattention is the central feature distinguishing subsyndromal states ^[100]^B2c.

Validated Rating Scales

Bedside instruments improve detection rates compared to unstructured clinical assessment alone ^[5]^A1a. The choice of tool depends on the clinical setting and the patient's ability to communicate.

CAM-ICU: Specifically designed for the intensive care setting, including mechanically ventilated patients ^[6]^A1a. It demonstrates high specificity (94.9%) for delirium in the ICU ^[142]^A1a.
4 A's Test (4AT): A brief tool with balanced accuracy, though it is unsuitable for patients receiving mechanical ventilation ^[142]^A1a.
Delirium Rating Scale-Revised-98 (DRS-R98): A 16-item scale used to assess symptom severity and distinguish full syndromal from subsyndromal delirium ^[99]^C4^[100]^B2c. A score of ≥12 is typically used for a full delirium diagnosis ^[100]^B2c.
Mini-Mental State Examination (MMSE): While common, a score <24 is the least useful for identifying delirium (LR 1.6; 95% CI 1.2-2.0) ^[5]^A1a.

Organic and Substance Rule-Out

Delirium is a medical emergency that necessitates a systematic search for underlying physiological precipitants. The workup must differentiate delirium from primary psychiatric disorders and stable dementia ^[116]^D5^[120]^B2b.

Laboratory Evaluation: Standard workup includes electrolytes, renal function, and inflammatory markers. Elevated C-reactive protein (CRP) and monocyte counts have been identified as predictors of delirium and subsequent psychiatric sequelae in acute illness ^[133]^B2b.
Substance-Induced States: Alcohol-induced delirium (delirium tremens) carries a high mortality rate, with 37% of patients dying within an 8-year follow-up period in some cohorts ^[98]^B2b.

Diagnostic Algorithm

Screen for Inattention: Use the Digit Span or Vigilance "A" test; however, these have limited utility in isolation and should trigger a full CAM if abnormal ^[5]^A1a^[100]^B2c.
Apply CAM/CAM-ICU Criteria: Confirm acute onset, fluctuation, and disorganized thinking or altered consciousness ^[5]^A1a^[6]^A1a.
Assess Severity: Utilize the DRS-R98 to establish a baseline for monitoring treatment response ^[99]^C4^[116]^D5.
Identify Precipitants: Order targeted labs (CBC, CMP, UA) and review the medication list for deliriogenic agents (e.g., benzodiazepines) ^[27]^A1b^[133]^B2b.

Pearl: The CAM is the most evidence-based bedside tool for non-ICU patients, while the MMSE should not be used to rule in or rule out delirium due to its poor diagnostic accuracy in this context ^[5]^A1a.

Diagnostic Accuracy of Bedside Instruments

Instrument	Sensitivity	Specificity	Positive LR (95% CI)	Negative LR (95% CI)
CAM	High	High	9.6 (5.8-16.0)	0.16 (0.09-0.29)
CAM-ICU	Variable	94.9%	-	-
MMSE (<24)	Low	Low	1.6 (1.2-2.0)	-
S-PTD	92.2%	97.7%	-	-

Severity, Course Specifiers and Risk Stratification

▸Delirium severity is characterized by the intensity of core cognitive deficits, particularly inattention and memory impairment, which are more pronounced in persistent cases.
▸Preoperative frailty and high anticholinergic burden (JARS ≥3) are primary clinical markers for stratifying the risk of postoperative and in-hospital delirium.
▸The PAWSS tool provides high-certainty risk stratification for alcohol-related delirium, with a score of 4 or more indicating a 174-fold increase in the likelihood of severe withdrawal.

HY High Yield: In patients with advanced cancer and agitated delirium, the combination of IV lorazepam and haloperidol is superior to haloperidol alone for rapid symptom reduction (RASS reduction of 4.1 vs 2.3 points) [153].

Risk stratification in delirium converts the clinical diagnosis into a severity and risk tier that dictates treatment intensity and setting. While the syndrome is inherently acute, its course and severity are heavily influenced by the patient's baseline physiological reserve and the potency of the precipitating insult ^[113]^B2a^[160]^B3b.

Severity and Course Specifiers

Delirium severity is not static; it fluctuates based on the degree of cognitive and non-cognitive symptom burden. Full syndromal delirium is distinguished from subsyndromal states by significantly greater severity in thought process abnormalities, delusions, hallucinations, and memory impairment ^[99]^C4. Persistent delirium, which fails to resolve during the acute hospital stay, involves an increasing prominence of core diagnostic features and cognitive deficits ^[99]^C4.

Subsyndromal Delirium: Characterized by fewer or less intense symptoms that do not meet full diagnostic criteria but still portend poor outcomes ^[99]^C4.
Persistent Delirium: Associated with greater disturbance in orientation, attention, and memory compared to resolving cases ^[99]^C4.
Agitated Delirium: A high-risk phenotype where severity is often measured by the Richmond Agitation-Sedation Scale (RASS). In patients with advanced cancer, adjuvant 3 mg IV added to 2 mg IV reduced RASS scores by 4.1 points compared to 2.3 points with haloperidol alone ^[153]^A1b.

Risk Stratification and Prognostic Markers

Stratifying risk involves assessing both preoperative vulnerability and acute biological markers. Preoperative frailty, measured by the Clinical Frailty Scale (CFS) or Liver Frailty Index (LFI), is a strong independent predictor of postoperative delirium (POD) ^[160]^B3b^[161]^B3b.

Marker Type	Specific Factor	Clinical Significance
Biomarkers	Plasma p-tau181 and IL-6	Preoperative elevation independently predicts POD after cardiac surgery ^[105]^B2b.
Imaging	White Matter Hyperintensities (WMH)	Worse WMH severity is independently associated with delirium (adjusted OR 2.9) ^[107]^A1a.
Clinical	Anticholinergic Burden	A Japanese Anticholinergic Risk Scale (JARS) score ≥3 is associated with incident delirium (adjusted OR 1.76) ^[50]^B2b.
Physiological	Frailty (CFS ≥5)	Independently associated with POD in liver transplant recipients (aOR 4.32) ^[160]^B3b.

Mortality and Long-Term Risk

Delirium is a pivotal marker of mortality and institutionalization risk. A meta-analysis of elderly patients found that delirium is associated with an increased risk of death (HR 1.95) after an average follow-up of 22.7 months ^[113]^B2a. Furthermore, an episode of delirium increases the odds of a new dementia diagnosis by 12.52 times over a 4-year follow-up period ^[113]^B2a. In the context of , acute delirium during hospitalization independently predicts new-onset psychiatric disorders up to 2 years later (HR 1.49) ^[133]^B2b.

Alcohol and Substance Withdrawal Risk

In patients at risk for alcohol withdrawal, the Prediction of Alcohol Withdrawal Severity Scale (PAWSS) is the most effective tool for stratification. A PAWSS score ≥4 identifies patients at high risk for severe (SAWS), including delirium tremens, with a likelihood ratio of 174 ^[65]^A1a. Conversely, a score of 3 or fewer effectively excludes SAWS (sensitivity 0.99) ^[65]^A1a.

Pearl: Delirium is a "brain stress test"; its occurrence even in subsyndromal forms indicates a high risk of permanent cognitive decline, with a 12-fold increased risk of future dementia ^[113]^B2a.

Risk Stratification Markers for Delirium

Marker	Threshold/Finding	Outcome Association
p-tau181 / IL-6	Preoperative elevation	Predicts POD after cardiac surgery ^[105]^B2b
WMH Severity	High burden on MRI	Associated with delirium (OR 2.9) ^[107]^A1a
JARS Score	≥3	Incident in-hospital delirium (OR 1.76) ^[50]^B2b
PAWSS Score	≥4	Severe alcohol withdrawal/DTs (LR 174) ^[65]^A1a
CFS/LFI	Frail status	4.3-fold increased risk of POD in transplant ^[160]^B3b

Acute Management and Psychiatric Emergencies

▸Antipsychotics like haloperidol and ziprasidone do not increase delirium-free days or improve survival in general ICU populations compared to placebo.
▸Dexmedetomidine is superior to benzodiazepines for maintaining targeted sedation levels and increasing delirium-free days in mechanically ventilated patients.
▸Multicomponent non-pharmacological interventions, including sleep promotion and early mobilization, remain the most effective strategy for delirium prevention and management.

! Warning: Avoid benzodiazepines for routine delirium management as they are associated with a higher prevalence of coma (92% vs 63%) and fewer delirium-free days compared to dexmedetomidine [167].

Rx Drug of Choice: Dexmedetomidine is preferred over lorazepam for sedation in mechanically ventilated patients to maximize days alive without delirium or coma (median 7.0 vs 3.0 days; P=0.01) [167].

Acute of delirium prioritizes the stabilization of time-critical physiological disturbances while ensuring the safety of the patient and staff. Because delirium is a potent indicator of patient safety and a marker of brain vulnerability, immediate intervention is required to prevent permanent cognitive damage ^[28]^D5 (5). The 'vulnerability-precipitant' model dictates that management must simultaneously address the acute trigger (e.g., sepsis, metabolic derangement) and the symptomatic manifestations that threaten the integrity of medical care ^[116]^D5 (5).

Step 1: Immediate Safety and Environmental Stabilization

Initial management focuses on non-pharmacological interventions to reduce agitation and prevent injury. Multicomponent risk factor approaches are the most effective strategy for prevention and are recommended as first-line for treatment ^[28]^D5^[116]^D5 (5).

Environmental Optimization: Implement sleep promotion, early mobilization, and reorientation protocols ^[74]^A1a^[116]^D5 (1a, 5).
Physical Restraints: Avoid systematic use of wrist-strap restraints. A randomized trial (n=405) found that a low-use restraint strategy (avoided unless RASS ≥3) did not significantly increase self-extubation (9.2% vs 8.5%) or mortality compared to high-use strategies ^[70]^A1b (1b).
Sensory Support: Ensure access to visual and hearing aids to reduce misperceptions ^[116]^D5 (5).
Complementary Therapies: and facial massage, with or without lavender , has been shown to improve sleep quality and reduce delirium severity in cardiac intensive care settings ^[122]^A1b (1b).

Step 2: Pharmacological Symptom Control

Pharmacological treatment is reserved for severe agitation that poses a risk to safety or threatens the interruption of essential medical therapies ^[116]^D5 (5). There is no convincing evidence that antipsychotics reduce the duration or severity of delirium in the general ICU population ^[25]^A1b^[110]^A1b (1b).

Antipsychotics: In the MIND-USA trial, (max 20 mg daily) and (max 40 mg daily) showed no significant difference compared to placebo in days alive without delirium or coma (8.5 days for placebo vs 7.9 for haloperidol and 8.7 for ziprasidone; P=0.26) ^[25]^A1b (1b). Similarly, the AID-ICU trial found no significant difference in 90-day mortality or days out of hospital with IV ^[110]^A1b (1b).
Alpha-2 Agonists: In mechanically ventilated patients with agitated delirium, increased ventilator-free hours (median 144.8 vs 127.5 hours; P=0.01) and accelerated delirium resolution (median 23.3 vs 40.0 hours; P=0.01) compared to placebo ^[152]^A1b (1b).
Benzodiazepines: Generally avoided as they may contribute to acute brain dysfunction ^[167]^A1b (1b). However, in palliative care for advanced cancer, the addition of 3 mg IV to 2 mg IV resulted in a significantly greater reduction in RASS scores (-4.1 vs -2.3 points; P<0.001) compared to haloperidol alone ^[153]^A1b (1b).

Step 3: Management of Specific Etiologies

Sepsis-Associated Encephalopathy: Emerging evidence suggests that -based anesthesia may improve hemodynamic stability and reduce vasopressor needs compared to propofol in septic patients ^[176]^B3b (3b).
Antibiotic-Associated Neurotoxicity: Patients receiving may experience fewer days free of delirium and coma (11.9 days) compared to those receiving (12.2 days) ^[101]^A1b (1b).

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength of Disagreement	Implication for Practice
Use of Antipsychotics	MIND-USA / AID-ICU Trials: No benefit for delirium duration or mortality in general ICU patients ^[25]^A1b^[110]^A1b.	Clinical Practice (Traditional): Frequently used for symptom control and agitation management ^[110]^A1b.	Strong	Antipsychotics should be reserved for safety-critical agitation rather than routine delirium treatment.
Sedation Strategy	Nonsedation: A plan of no sedation in mechanically ventilated patients is feasible and does not increase 90-day mortality ^[109]^A1b.	Light Sedation: Targeting RASS -2 to -3 with daily interruption is a standard alternative ^[109]^A1b.	Moderate	Nonsedation may reduce thromboembolic events but requires high nursing ratios.

Pearl: Prioritize non-pharmacological environmental interventions and the treatment of underlying causes; reserve antipsychotics for severe agitation, as they do not shorten delirium duration or improve survival in the ICU (MIND-USA, AID-ICU) ^[25]^A1b^[110]^A1b^[116]^D5.

Pharmacological Management Options in Delirium

Indication	Dose (if reported)	Evidence Level	Key Outcome
Agitated delirium (ICU)	0.5 to 1.5 µg/kg/h IV	1b ^[152]^A1b	Increased ventilator-free hours (median diff 17h)
Severe agitation	2.5 mg TID + 2.5 mg PRN (max 20 mg/d)	1b ^[110]^A1b	No significant difference in days alive/out of hospital
Palliative agitation	3 mg IV (adjunct to haloperidol)	1b ^[153]^A1b	Greater RASS reduction (-4.1 vs -2.3)
Prevention (Elderly)	8 mg PO nightly	1b ^[2]^A1b	Reduced delirium incidence (3% vs 32%)
ICU Delirium	Max 40 mg daily	1b ^[25]^A1b	No significant effect on delirium-free days

Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies

▸Non-pharmacological multicomponent interventions reduce delirium incidence by approximately 31% in hospitalized patients.
▸Pharmacological treatment of established delirium with antipsychotics does not reduce delirium duration or improve survival in the ICU.
▸Early discontinuation of antipsychotics after hospital discharge significantly reduces the risk of rehospitalization and all-cause mortality.

! Warning: Do NOT use [[rivastigmine]] for the treatment of delirium in critically ill patients; it has been associated with a near-tripling of mortality (22% vs 8%) and longer delirium duration [24].

HY High Yield: Antipsychotic use in patients with dementia carries a significant mortality risk. The Number Needed to Harm (NNH) for one death is 26 for [[haloperidol]], 27 for [[risperidone]], 40 for [[olanzapine]], and 50 for [[quetiapine]] [188].

Transitioning from the stabilization of acute psychiatric emergencies requires a structured approach to definitive , prioritizing non-pharmacological foundations before escalating to pharmacological or somatic interventions. The 'vulnerability-precipitant' model dictates that long-term resolution depends on mitigating chronic risk factors while managing the residual effects of acute insults ^[116]^D5 (5).

Step 1: Non-Pharmacological Multicomponent Interventions

Multicomponent non-pharmacological interventions are the gold standard for reducing delirium incidence in hospital settings ^[30]^A1a (1a). These strategies target cognitive stimulation, early mobilization, visual and hearing aids, and sleep hygiene.

Hospitalized Non-ICU Patients: Multicomponent interventions reduce delirium incidence by 31% (RR 0.69, 95% CI 0.59-0.81) ^[30]^A1a (1a).
Long-Term Care (LTC): Evidence for multicomponent interventions in LTC is less robust, though hydration-based protocols have been explored without significant reduction in incidence in small trials ^[82]^A1a^[183]^A1a (1a).
Psychosocial Support: Providing relatives with information via flyers or videos improves delirium knowledge, though clear effects on psychological outcomes for caregivers remain unproven ^[118]^D5 (5).
Complementary Modalities: and facial massage, with or without lavender aromatherapy, administered twice daily for 20 minutes, improves sleep quality and reduces delirium severity in cardiac intensive care settings ^[122]^A1b (1b).

Step 2: Pharmacological Prophylaxis and Prevention

Pharmacological prevention is generally more successful than treatment of established delirium ^[106]^A1a (1a).

Esketamine and Ketamine: Perioperative esketamine is associated with a significantly lower incidence of postoperative delirium (RR 0.55, 95% CI 0.46-0.67) ^[186]^A1a (1a). In pediatric populations, low-dose esketamine (< 0.5 mg/kg) reduces emergence agitation (OR 0.33, 95% CI 0.20-0.53) ^[187]^A1a (1a). Conversely, a single intraoperative dose of ketamine (0.5 mg/kg or 1.0 mg/kg) did not reduce and increased postoperative hallucinations ^[60]^A1b (1b).
Melatonin Agonists: has demonstrated significant preventive effects (OR 0.07, 95% CI 0.01-0.66) compared to placebo ^[57]^A1a (1a).

Step 3: Pharmacotherapy for Symptom Management

Pharmacological treatment of established delirium does not typically reduce duration or mortality, and should be reserved for distressing symptoms ^[110]^A1b^[155]^A1a.

Antipsychotics: Neither nor significantly altered the number of days alive without delirium or coma in ICU patients compared to placebo ^[25]^A1b (1b). In the AID-ICU trial, haloperidol (2.5 mg 3 times daily) did not increase days alive and out of hospital at 90 days (35.8 vs 32.9 days, P = 0.22) ^[110]^A1b (1b).
Combination Therapy: For agitated delirium in palliative care, the combination of intravenous lorazepam (3 mg) and haloperidol (2 mg) reduced RASS scores by 4.1 points compared to 2.3 points with haloperidol alone (P < 0.001) ^[153]^A1b (1b).
Cholinesterase Inhibitors: Do NOT use for delirium; it does not decrease duration and may increase mortality (22% vs 8% placebo, P = 0.07) ^[24]^A1b (1b).

Step 4: Somatic and Emerging Therapies

Virtual Reality (VR): Immersive VR interventions significantly reduce preoperative anxiety in pediatric patients (SMD -0.69, 95% CI -0.96 to -0.42), which may mitigate subsequent emergence delirium ^[194]^A1a (1a).
Novel Sedatives: with reversal reduces emergence agitation (20.7% vs 48.3% with desflurane, P = 0.027) and shortens emergence time ^[91]^A1b (1b).

Step 5: Discontinuation and Long-Term Monitoring

Early discontinuation of antipsychotics initiated for delirium is critical. Discontinuing these agents (gap ≥ 45 days) is associated with lower risks of rehospitalization (HR 0.89, 95% CI 0.85-0.94) and all-cause mortality (HR 0.77, 95% CI 0.69-0.86) compared to continuation ^[88]^B2b (2b).

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Prophylactic Antipsychotics	Wu et al. ^[57]^A1a, Meta-analysis suggests olanzapine and risperidone significantly lower delirium occurrence.	REDUCE Trial ^[179]^A1b, Prophylactic haloperidol (1 mg or 2 mg) did not improve 28-day survival or reduce delirium incidence.	Strong	Prophylaxis with typical antipsychotics is not supported for mortality benefit; second-generation agents may have a role in specific surgical prophylaxis.
Dexmedetomidine in Cardiac Surgery	Su et al. ^[23]^A1b, Strong evidence for prevention in non-cardiac surgery.	DECADE Trial ^[59]^A1b, No benefit in cardiac surgery; non-significant increase in delirium.	Moderate	Efficacy of dexmedetomidine for prevention is highly dependent on the surgical context and population.
Terminal Dehydration	Traditional View, Artificial hydration prevents delirium and thirst in the dying.	Correa-Morales et al. ^[195]^D5, Dehydration is an adaptive process; hydration increases respiratory secretions and agitation.	Moderate	Reduced hydration may improve comfort in the terminal phase.

Pearl: Prioritize non-pharmacological multicomponent bundles for prevention (NNT = 8 for dexmedetomidine in non-cardiac surgery) and ensure rapid discontinuation of any antipsychotics post-discharge to reduce mortality risk (HR 0.77) ^[23]^A1b^[88]^B2b.

Pharmacological Comparison for Delirium Prevention and Treatment

Agent	Indication	Key Finding	Effect Size	Evidence Level
	Prevention (Non-cardiac surgery)	Reduced incidence vs placebo	9% vs 23% (OR 0.35)	1b ^[23]^A1b
	Prevention (Perioperative)	Reduced incidence of POD	RR 0.55 (95% CI 0.46-0.67)	1a ^[186]^A1a
	Treatment (ICU)	No difference in days alive/out of hospital	35.8 vs 32.9 days (P=0.22)	1b ^[110]^A1b
+ Haloperidol	Treatment (Agitated/Palliative)	Greater RASS reduction vs Haloperidol alone	-4.1 vs -2.3 points (P<0.001)	1b ^[153]^A1b
	Prevention	Lower occurrence rates	OR 0.07 (95% CI 0.01-0.66)	1a ^[57]^A1a
	Treatment (ICU)	Increased mortality (Harmful)	22% vs 8% (P=0.07)	1b ^[24]^A1b

Dosing and Monitoring for Delirium Management

Starting dose	Target / max dose	Renal / Hepatic adjustment	Key monitoring
2.5 mg IV (TID)	20 mg/day	No specific adjustment in abstracts	QTc interval, EPS
0.1 μg/kg/h	0.7 μg/kg/h	No adjustment reported	HR, BP (Bradycardia/Hypotension)
3 mg IV (adjunct)	Single dose for agitation	Use with caution in hepatic failure	Respiratory rate, sedation level
< 0.5 mg/kg	Subanaesthetic dose	Not specified in abstracts	Hallucinations, nightmares

Psychopharmacology Monitoring and Safety Surveillance

▸Continuous ECG monitoring is not required for cumulative IV haloperidol doses <2 mg in patients without baseline risk factors.
▸VMAT2 inhibitors carry a 61% lower risk of incident delirium compared to anticholinergic agents when managing movement disorders.
▸Delirium status is a significant predictor of lost functional independence (Katz scale) but does not consistently alter gross muscle strength (MRC-SS) in thoracic surgery populations.

! Warning: Anticholinergic agents used for EPS can exacerbate delirium and cognitive impairment; VMAT2 inhibitors are preferred for tardive dyskinesia to reduce delirium risk (HR 0.39) [205, 207].

HY High Yield: In cases of IV haloperidol-associated Torsades de Pointes, 96% of patients exhibit a QTc >450 ms prior to the event [204].

Transitioning from acute symptom to ongoing care requires a protocolized approach to safety surveillance, particularly regarding the cardiac and cognitive risks associated with antipsychotic and anticholinergic therapies. While remains a mainstay for managing agitation, its intravenous (IV) administration necessitates specific monitoring thresholds to mitigate the risk of QT prolongation and torsades de pointes (TdP) ^[201]^A1a^[204]^D5.

Cardiac and ECG Monitoring

Cardiac safety monitoring for IV is risk-stratified based on cumulative exposure and baseline electrophysiology. Although IV does not consistently cause greater QT prolongation than placebo in prospective studies, TdP has been reported in patients receiving cumulative doses ranging from 5 mg to 645 mg ^[201]^A1a^[204]^D5. In 96% of cases where TdP occurred, the QTc was prolonged to >450 ms ^[204]^D5.

Low-dose threshold: Cumulative doses <2 mg can generally be administered without continuous electrocardiographic monitoring in patients lacking other proarrhythmic risk factors ^[204]^D5.
ECG monitoring: Recommended for any single dose >5 mg ^[201]^A1a.
Telemetry: Indicated for high-risk patients receiving cumulative doses of ≥100 mg or those with a corrected QTc >500 ms ^[201]^A1a.

Autonomic and Cognitive Surveillance

Monitoring must account for the high burden of iatrogenic complications, particularly when using agents with anticholinergic properties. Anticholinergic drugs, often used to treat extrapyramidal symptoms (EPS), are associated with central adverse effects including cognitive impairment and the worsening of delirium ^[205]^D5. In patients with , the use of (e.g., , ) is associated with a significantly lower risk of delirium (HR 0.39, 95%) compared to anticholinergic agents ^[207]^B3b.

Supportive Care and Complication Prevention

Delirium management extends beyond neuroleptics to the prevention of hospital-acquired complications and the maintenance of physical function. While delirium is associated with a significant change in functional independence (Katz score change in 13% of delirious vs 0% of non-delirious patients), it may not directly correlate with changes in gross muscle strength as measured by the Medical Research Council sum score (MRC-SS) ^[199]^B2b.

Complication	Frequency/Risk	Prevention/Monitoring	Management
QT Prolongation	High in polypharmacy	Baseline ECG; monitor if dose >5 mg ^[201]^A1a	Discontinue offending agents; correct electrolytes
Torsades de Pointes	Low (associated with QTc >500 ms)	Telemetry for cumulative doses >100 mg ^[201]^A1a	Magnesium sulfate; telemetry
Cognitive Decline	High with anticholinergics	Avoid prophylactic anticholinergics ^[205]^D5	Switch to for EPS ^[207]^B3b
Functional Loss	13% (Katz score change) ^[199]^B2b	Early mobilization; ADL assessment	Physical and occupational therapy

Pain and Sedation Management

Selection of and analgesic agents must prioritize the avoidance of delirium-inducing compounds. While is relatively benign in overdose (median dose 420 mg) and is not typically associated with delirium or QT prolongation, its use in polypharmacy increases the risk of CNS depression ^[206]^C4. Conversely, agents like used for Parkinsonian symptoms can directly cause hallucinations, confusion, and delirium ^[203]^D5.

Pearl: For patients requiring IV , the transition to telemetry is mandatory once the cumulative dose reaches 100 mg or the QTc exceeds 500 ms to prevent fatal arrhythmias ^[201]^A1a.

Monitoring Requirements for Intravenous Haloperidol

Parameter	Threshold/Criteria	Monitoring Requirement
Single Dose	>5 mg	Electrocardiogram (ECG) ^[201]^A1a
Cumulative Dose	<2 mg	No routine monitoring if no risk factors ^[204]^D5
Cumulative Dose	≥100 mg	Continuous Telemetry ^[201]^A1a
QTc Interval	>500 ms	Continuous Telemetry ^[201]^A1a

Risk and Safety Assessment, Capacity and Therapeutic Setting

▸Delirium in pneumonia is associated with a 4.3-fold increase in mortality, emphasizing the need for aggressive safety monitoring regardless of the microbiological cause [212].
▸The PAWSS tool is highly effective for stratifying alcohol withdrawal risk; a score of 4 or more carries a likelihood ratio of 174 for developing severe withdrawal or delirium tremens [65].
▸Non-pharmacological volunteer interventions can reduce the incidence of in-hospital delirium by approximately 10% (OR 0.55) [217].

! Warning: Systemic glucocorticoid therapy is associated with a 5.14-fold increased risk of delirium and a 6.89-fold increased risk of suicide or suicide attempt [73].

HY High Yield: Preoperative cognitive impairment is one of the strongest predictors of postoperative delirium, increasing the risk by up to 17-fold in some surgical cohorts (adjusted OR 17.0) [164].

Safety surveillance in the context of delirium requires immediate assessment of self-harm, violence, and self-neglect, as the acute fluctuation in awareness often impairs a patient's ability to maintain their own safety or cooperate with care. Beyond the immediate neuropsychiatric symptoms, delirium is an independent driver of severe outcomes; for instance, in patients with pneumonia, the presence of delirium is associated with a 4.3-fold increase in mortality (OR 4.3, 95%) ^[212]^B2a.

Risk Stratification and Safety Assessment

Structured risk assessment must prioritize identifying patients at high risk for severe complications, including attempts and severe alcohol withdrawal. In primary care settings, systemic therapy significantly elevates these risks, with a hazard ratio of 6.89 (95% CI 4.52-10.50) for suicide or suicide attempt and 5.14 (95% CI 4.54-5.82) for delirium or confusion ^[73]^B2b. Younger patients are at particularly high risk for suicidal behavior following steroid exposure, while older men are more prone to delirium and mania ^[73]^B2b.

For patients at risk of , the Prediction of Alcohol Withdrawal Severity Scale (PAWSS) is the most effective tool for identifying those likely to develop or seizures ^[65]^A1a.

Low-Risk PAWSS Threshold: A score of 3 or fewer findings (LR 0.07, 95% CI 0.02-0.26; sensitivity 0.99) ^[65]^A1a.
Clinical Red Flags: A history of delirium tremens (LR 2.9) and a baseline systolic blood pressure ≥140 mm Hg (LR 1.7) are strong predictors of severe withdrawal ^[65]^A1a.

Capacity, Consent, and Involuntary Care

Delirium inherently fluctuates, necessitating frequent reassessment of for medical decisions. While patients may retain capacity for simple tasks, the presence of preoperative cognitive impairment increases the risk of postoperative delirium (POD) with an adjusted OR of 2.2 ^[164]^D5. In cases of severe agitation or self-neglect where the patient lacks capacity and poses a risk to themselves or others, involuntary care in the least restrictive setting is required to facilitate life-saving treatment.

Therapeutic Setting and Optimization

The therapeutic setting should be optimized to minimize iatrogenic harm and promote orientation. Volunteer-led programs, such as Delirium Optimization with Volunteer Engagement (DOVE), have demonstrated that structured non-pharmacological interventions (sensory aids, conversation, and orientation) can reduce in-hospital delirium occurrence from 56.7% to 46.8% (OR 0.55, 95% CI 0.34-0.89) ^[217]^B3b.

In the surgical setting, frailty indices are superior to comorbidity-only scales for predicting the need for higher-acuity settings or non-home discharge ^[216]^B3b. The Modified Four-Factor Functional Frailty Index (mFF-4) identifies high-risk patients (score 2+) who have a >2.0 odds ratio for delirium and non-home discharge ^[216]^B3b.

Predictive Modeling for Safety Planning

Machine learning (ML) models and clinical scales help clinicians anticipate safety needs before delirium manifests.

Tool/Model	Population	Performance (AUC/OR)	Key Predictors
JARS (Anticholinergic Scale)	Acute Geriatric	OR 1.76 (JARS ≥3) ^[50]^B2b	Anticholinergic burden, baseline cognition
Random Forest ML	Elective Surgery	AUC 0.89 ^[211]^B2a	Age, cognitive impairment, albumin ^[211]^B2a
RAI-rev (Risk Analysis Index)	Abdominal Surgery	AUC 0.79 ^[215]^B2b	Frailty, nutrition (NRS 2002), triglycerides
GBT Algorithm	General Surgery	AUC 0.83 ^[214]^B2b	Preoperative data + postoperative lab changes

While ML models show moderate-to-high accuracy (pooled AUROC 0.82-0.83), their clinical utility is currently limited by a high risk of bias in analysis and a lack of external validation ^[209]^B2a^[210]^B2a^[211]^B2a.

Pearl: In patients receiving systemic glucocorticoids, the risk of suicide or suicide attempt increases nearly seven-fold (HR 6.89), necessitating proactive safety planning and family education even in those without prior psychiatric history ^[73]^B2b.

Predictive Performance of Delirium Risk Tools

Tool	Target Population	Metric	Clinical Significance
PAWSS	Alcohol Withdrawal	LR 174 (Score ≥4)	Identifies patients at high risk for DTs/seizures ^[65]^A1a
JARS	Geriatric Inpatients	OR 1.76 (Score ≥3)	High anticholinergic burden predicts incident delirium ^[50]^B2b
mFF-4	Colorectal Surgery	AUC >0.70	Predicts delirium and non-home discharge better than mFI-5 ^[216]^B3b
ML Models	Non-cardiac Surgery	AUC 0.82	Moderate-to-high accuracy but limited by bias/validation ^[210]^B2a

History and Evolution of Treatment

▸Antipsychotics like haloperidol and ziprasidone do not reduce delirium duration or improve 90-day survival in general ICU populations.
▸Symptom-triggered benzodiazepine protocols are superior to fixed-schedule dosing for alcohol withdrawal, reducing medication exposure by over 75%.
▸Early physical and occupational therapy combined with sedation interruption halves the median duration of delirium in mechanically ventilated patients.

HY High Yield: The MIND-USA trial is the definitive evidence base for the lack of efficacy of haloperidol and ziprasidone in treating hypoactive or hyperactive delirium in the ICU [25].

! Warning: Rivastigmine should not be used to treat delirium in critically ill patients due to a trend toward increased mortality (22% vs 8%) [24].

The conceptual history of delirium shifted in the 19th century from a broad psychiatric category to a specific manifestation of acute brain failure, characterized by clouding of consciousness and cognitive failure ^[224]^D5. Modern has evolved from a reliance on sedation and "organic" rule-outs to a evidence-based framework that prioritizes non-pharmacological prevention and the avoidance of iatrogenic harm ^[28]^D5^[225]^D5.

The Rise and Fall of Pharmacological Prophylaxis

Early treatment models frequently utilized antipsychotics and benzodiazepines as primary interventions, but landmark trials have largely overturned these practices for general delirium. The MIND-USA trial demonstrated that neither (maximum 20 mg daily) nor (maximum 40 mg daily) significantly altered the number of days alive without delirium or coma compared to placebo (8.5 days for placebo vs. 7.9 for haloperidol; P=0.26) ^[25]^A1b. Similarly, the AID-ICU trial found that haloperidol (2.5 mg three times daily) did not increase the number of days alive and out of the hospital at 90 days (35.8 days vs. 32.9 for placebo; P=0.22) ^[110]^A1b.

Intervention	Landmark Finding	Clinical Impact
	Increased mortality (22% vs. 8%; P=0.07) and longer delirium duration ^[24]^A1b.	Abandoned in critical care settings.
	No reduction in postoperative delirium; increased hallucinations and nightmares ^[60]^A1b.	Not recommended for delirium prevention.
	No effect on delirium incidence (8% vs. 8%) in cardiac surgery ^[221]^A1b.	Limited to inflammatory indications.
	Reduced delirium risk (3% vs. 32%; RR 0.09) in elderly acute care patients ^[2]^A1b.	Emerging role for melatonin agonists.

Evolution of Sedation Paradigms

The transition from deep sedation to "light sedation" or "no sedation" protocols represents a major shift in critical care. The SPICE III trial showed that early sedation with resulted in similar 90-day mortality (29.1%) to usual care, though it required supplemental sedatives in 64% of patients ^[131]^A1b. While the SEDCOM trial found dexmedetomidine reduced delirium prevalence compared to (54% vs. 76.6%; P < 0.001) ^[27]^A1b, more recent data from the A2B trial (2025) indicated no significant difference in time to successful extubation between dexmedetomidine, , and ^[26]^A1b^[45]^A1b.

Refinement of Alcohol Withdrawal Management

Treatment of alcohol-induced delirium (delirium tremens) evolved from fixed-schedule dosing to symptom-triggered regimens. Meta-analysis confirmed that reduce the incidence of delirium by 4.9 cases per 100 patients (95% CI, -9.0 to -0.7) ^[219]^A1c. Symptom-triggered therapy with reduced the median duration of treatment from 68 hours to 9 hours (P < .001) and total dose from 425 mg to 100 mg (P < .001) without increasing the risk of seizures or delirium tremens ^[223]^A1b.

Emergence of Multimodal and Non-Pharmacological Care

Current standards emphasize early mobilization and environmental optimization. Combining daily interruption of sedation with physical and occupational therapy reduced delirium duration from a median of 4.0 days to 2.0 days (P=0.02) ^[108]^A1b. While flexible family visitation (up to 12 hours/day) improved family anxiety and depression, it did not significantly reduce delirium incidence (18.9% vs. 20.1%;) ^[69]^A1b. Recent investigations into neuromodulation, such as transauricular vagus nerve stimulation (taVNS), have shown a reduction in postoperative cognitive dysfunction (10.2% vs. 32.7%; P=0.006) but no significant difference in acute delirium ^[140]^A1b.

Pearl: The evolution of delirium care has moved from "treating the agitation" with neuroleptics to "treating the brain" through sedation minimization and early mobilization, as large-scale RCTs consistently show no benefit for antipsychotics in reducing delirium duration ^[25]^A1b^[110]^A1b.

Evolution of Pharmacological Evidence in Delirium

Drug Class	Historical Use	Current Evidence Status
Antipsychotics	First-line treatment	No effect on delirium-free days in MIND-USA ^[25]^A1b or AID-ICU ^[110]^A1b.
Cholinesterase Inhibitors	Proposed for cholinergic deficit	Rivastigmine increased mortality and delirium duration ^[24]^A1b.
Alpha-2 Agonists	Alternative to GABA-ergics	Dexmedetomidine reduces delirium vs. midazolam ^[27]^A1b but not vs. propofol ^[222]^A1b.
Melatonin Agonists	Circadian regulation	Ramelteon (8 mg) showed significant preventive efficacy (RR 0.09) ^[2]^A1b.

Complications, Comorbidity and Iatrogenic Harm

▸Delirium is associated with a nearly twofold increase in mortality (HR 1.95) and a twelvefold increase in dementia risk (OR 12.52).
▸Early physical and occupational therapy significantly improves functional independence at discharge (OR 2.7) and reduces delirium duration.
▸Discontinuing antipsychotics initiated for delirium at the time of hospital discharge reduces the risk of rehospitalization and all-cause mortality.

! Warning: Antipsychotic use in older adults with dementia carries a high risk of mortality; the NNH for one death is as low as 26 for haloperidol [188].

Building upon the historical evolution of , modern supportive care focuses on mitigating the substantial morbidity and mortality associated with acute brain dysfunction. Delirium is not a transient state but a driver of long-term poor outcomes, including a significantly increased risk of death (HR 1.95 ^[113]^B2a), institutionalization (OR 2.41 ^[113]^B2a), and a twelvefold increase in the risk of developing dementia (OR 12.52 ^[113]^B2a).

Hospital-Acquired and Medical Complications

Patients with delirium are highly susceptible to secondary medical insults that prolong hospitalization and increase resource utilization. In populations, medical complications occur in 23% of patients, with infections being the most frequent ^[94]^B2b.

Infectious: Pneumonia (6%) and urinary tract infections (5%) are the leading medical complications ^[94]^B2b.
Metabolic/Nutritional: Dehydration occurs in 2% of surgical cases ^[94]^B2b.
Surgical: Major reoperations (2%) and prosthesis dislocation (2%) are common in orthopedic cohorts ^[94]^B2b.
Thromboembolic: While sedation strategies vary, major thromboembolic events occurred in 2.8% of patients receiving light sedation compared to 0.3% in those receiving no sedation ^[109]^A1b.

Iatrogenic Harm and Medication Safety

Pharmacological management often introduces secondary risks, particularly when using or .

Antipsychotic Risks: Discontinuing after hospital discharge is associated with lower risks of rehospitalization (HR 0.89), inpatient delirium (HR 0.87), and all-cause mortality (HR 0.77) ^[88]^B2b. In dementia patients, the number needed to harm (NNH) for one death is 26 for and 27 for ^[188]^B2b.
Sedation-Related Harm: Use of to treat delirium in the ICU was halted due to a trend toward increased mortality (22% vs 8% in placebo) ^[24]^A1b.
Physical Restraints: A low-use wrist-strap strategy did not reduce days free of delirium or coma compared to liberal use, with self-extubation occurring in approximately 8.5% to 9.2% of patients across both strategies ^[70]^A1b.

Supportive Care and Rehabilitation

Early intervention and non-pharmacological support are critical for functional recovery. Early physical and occupational therapy combined with daily sedation interruption increased the rate of return to independent functional status (59% vs 35%, OR 2.7) and shortened delirium duration (median 2.0 vs 4.0 days) ^[108]^A1b.

Complication	Frequency	Prevention/Management
Pneumonia	6% ^[94]^B2b	Early mobilization, aspiration precautions ^[108]^A1b
UTI	5% ^[94]^B2b	Prompt catheter removal, hydration ^[94]^B2b
Falls	Noted ^[88]^B2b	Discontinuation of (HR 0.77 for fall-related ED visits) ^[88]^B2b
Dementia	OR 12.52 ^[113]^B2a	Multicomponent non-pharmacological prevention ^[74]^A1a

Pearl: Delirium is a potent predictor of long-term cognitive decline; even after the acute episode resolves, patients face a twelvefold increased risk of dementia ^[113]^B2a.

Common Medical and Surgical Complications in Delirium

Complication	Incidence (Hip Fracture Cohort)	Impact on Mortality
Any Medical Complication	23%	Threefold increase ^[94]^B2b
Pneumonia	6%	Associated with 11% mortality ^[94]^B2b
Urinary Tract Infection	5%	Most common infectious complication ^[94]^B2b
Any Surgical Complication	4%	Associated with 11% mortality ^[94]^B2b
Delirium (Postoperative)	2%	Driver of poor functional recovery ^[94]^B2b^[169]^D5

Prognosis and Natural History

▸Early mobilization in the ICU can halve the median duration of delirium from 4.0 to 2.0 days [108].
▸Delirium independently accelerates cognitive decline by -0.37 MMSE points per year, separate from the effects of classic dementia pathology [120].
▸Glucocorticoid-induced delirium is associated with a nearly sevenfold increase in the hazard ratio for suicide or suicide attempts [73].

HY High Yield: The 'vulnerability-precipitant' model is reflected in the prognosis: patients with high white matter hyperintensity burden (OR 2.9) or pre-existing dementia experience the most aggressive cognitive decline following an acute episode [107, 120].

Postoperative and critical illness episodes typically resolve within days, though the trajectory is highly variable and often punctuated by persistent cognitive deficits. In patients undergoing major surgery, the median duration of delirium is approximately 2.0 to 4.0 days ^[108]^A1b. While acute symptoms may remit, the condition is independently associated with accelerated long-term cognitive decline, contributing an additional -0.37 MMSE points per year beyond the decline attributable to dementia pathology alone ^[120]^B2b.

Episode Duration and Recovery

Recovery rates depend heavily on the clinical setting and the implementation of early mobility protocols. In mechanically ventilated patients, early physical and occupational therapy can reduce the median duration of delirium from 4.0 days to 2.0 days (p=0.02) ^[108]^A1b. Conversely, certain pharmacological interventions may inadvertently prolong the course; for instance, the use of as an adjunct to in the ICU was associated with a longer median duration of 5.0 days compared to 3.0 days with placebo (p=0.06) ^[24]^A1b.

Mortality and Long-Term Outcomes

Delirium serves as a potent predictor of both short-term and long-term mortality, particularly in specialized populations. In patients with sepsis-associated delirium, higher monocyte-to-lymphocyte ratios (MLR) are independently associated with increased 28-day all-cause mortality (HR 1.08, 95% CI 1.02-1.15) ^[243]^B3b.

Outcome Metric	Statistical Impact	Clinical Significance
Cognitive Decline	-0.72 MMSE points/year	Combined effect of delirium and dementia pathology ^[120]^B2b
Mortality (Sepsis)	21.6% at 28 days	High-risk quartile (MLR) HR 1.44 ^[243]^B3b
Suicide Risk	HR 6.89 (95% CI 4.52-10.50)	Associated with glucocorticoid-induced delirium ^[73]^B2b
Functional Status	OR 2.7 for independence	Improved by early mobilization ^[108]^A1b

Predictors of Clinical Course

Forecasting the course of delirium requires assessment of both baseline vulnerability and acute physiological stressors. Key predictors of a prolonged or complicated course include:

Surgical Factors: In cardiac surgery, prolonged cardiopulmonary bypass time and mechanical ventilation time are significant predictors of postoperative delirium ^[18]^B2a.

Persistent delirium, characterized by increasing prominence of core diagnostic features and cognitive impairment, is more common in patients with diminished cognitive reserve ^[99]^C4^[241]^D5. While follow-up services for ICU survivors aim to address post-intensive care syndrome (PICS), evidence regarding their effectiveness in improving long-term cognitive function remains uncertain ^[135]^A1a.

Pearl: Delirium is not merely a transient state but a catalyst for permanent cognitive attrition; the combination of delirium and pre-existing dementia pathology nearly doubles the rate of annual MMSE decline compared to either condition alone ^[120]^B2b.

Prognostic Impact of Delirium

Outcome	Effect Size	Source
28-Day Mortality (Sepsis)	21.6% overall; HR 1.44 in high MLR	^[243]^B3b
Annual MMSE Decline	-0.72 points (Delirium + Dementia)	^[120]^B2b
Return to Independent Function	59% (Intervention) vs 35% (Control)	^[108]^A1b
Suicide/Attempt Risk	HR 6.89 (Glucocorticoid-exposed)	^[73]^B2b

Special Populations, Pregnancy and Perinatal Psychiatry

▸Elderly patients have a 2.4-fold increased risk of institutionalization following a delirium episode.
▸Low-dose dexmedetomidine (0.1 μg/kg/h) is an effective prophylactic agent for postoperative delirium in the elderly.
▸Antipsychotic use for delirium in patients with dementia is associated with a significant dose-response increase in mortality risk.

! Warning: Avoid [[rivastigmine]] for delirium in critically ill patients; a randomized trial was halted early due to a nearly 3-fold increase in mortality (22% vs 8%) [24].

HY High Yield: In the perinatal period, ultra-rapid onset of psychiatric symptoms (within 24-48 hours) should prompt immediate evaluation for NMDAR-antibody encephalitis rather than assuming a primary psychiatric diagnosis [245].

Prognostic outcomes in vulnerable groups are heavily influenced by baseline physiological reserve and the specific risks associated with pharmacological interventions. In these populations, the clinical approach shifts from standard protocols to highly modified strategies that account for developmental stages, reproductive safety, and the heightened risk of iatrogenic harm.

Geriatric Populations

Elderly patients (aged 65 to 89 years) represent the highest-risk cohort for delirium, with incidence rates reaching 23% in postoperative settings such as repair ^[23]^A1b^[94]^B2b. In this population, delirium is a potent predictor of long-term cognitive decline, institutionalization (OR 2.41, 95%), and mortality (HR 1.95, 95%) ^[113]^B2a.

: Antipsychotic use in elderly patients with dementia carries a high mortality risk; is associated with an NNH of 26, while has an NNH of 50 ^[188]^B2b. Discontinuing antipsychotics after hospital discharge reduces the risk of subsequent inpatient delirium (HR 0.87) and falls (HR 0.77) ^[88]^B2b.

Pediatrics and Adolescents

Delirium in hospitalized children is often linked to sleep disruption and the intensive care environment ^[77]^A1a.

Diagnosis: Assessment requires age-adjusted tools, as developmental maturation influences sleep architecture and cognitive presentation ^[77]^A1a.
Interventions: Non-pharmacological sleep promotion, including massage and bedtime stories, is prioritized to mitigate modifiable risk factors ^[77]^A1a. Unlike adults, there is limited evidence for pharmacological prevention in this group.

Pregnancy and Perinatal Psychiatry

Perinatal delirium is rare but represents a psychiatric emergency, often requiring differentiation from ^[245]^B3b.

Differential Diagnosis: must be considered, as it presents with ultra-rapid onset (median 1 day) and abundant psychopathology (92%) that can mimic primary psychosis ^[245]^B3b.
Treatment Safety: Management must balance maternal stability with fetal/neonatal safety. While specific teratogenicity data for acute delirium treatment is sparse, the use of or atypical antipsychotics requires careful monitoring for neonatal extrapyramidal symptoms if used near delivery.

Medically Comorbid and Immunocompromised

In patients with severe systemic illness, such as or sepsis, delirium serves as a marker of neuroinflammation ^[128]^D5^[132]^A1b.

COVID-19: Acute delirium during COVID-19 hospitalization independently predicts new-onset psychiatric disorders up to 2 years post-infection (HR 1.49, 95% CI 1.28-1.74) ^[133]^B2b. High concentrations of IL-6 in these patients disrupt neurogenesis ^[128]^D5.
Critical Illness: In mechanically ventilated patients, early physical and occupational therapy reduces delirium duration (median 2.0 vs 4.0 days; p=0.02) ^[108]^A1b. Conversely, is contraindicated in the ICU as it may increase mortality (22% vs 8%) ^[24]^A1b.

Pearl: In elderly patients, every day of delirium increases the risk of permanent cognitive impairment similar to moderate traumatic brain injury; prioritize non-pharmacological prevention over antipsychotics, which carry an NNH as low as 26 for mortality ^[112]^B2b^[188]^B2b.

Pharmacological Prevention Outcomes in Special Populations

Population	Outcome (Incidence)	Effect Size (95% CI)	NNT
Elderly (Acute Care)	3% vs 32% (Placebo)	RR 0.09 (0.01-0.69)	4 ^[2]^A1b
Elderly (Cardiac Surgery)	10% vs 28% (Placebo)	HR 2.8 (1.1-7.8)	6 ^[71]^A1b
Elderly (Major Surgery)	19.5% vs 19.8% (Placebo)	No Difference	N/A ^[60]^A1b

Prevention, Screening and Early Intervention

▸Prophylactic low-dose dexmedetomidine (0.1 μg/kg/h) reduces postoperative delirium incidence by 60% in elderly ICU patients (NNT = 8).
▸The Confusion Assessment Method (CAM) is the most accurate bedside instrument for diagnosis, while the MMSE is clinically inadequate for delirium screening.
▸Non-pharmacological bundles, including music therapy and environmental optimization, are high-quality evidence-based strategies for primary prevention.

HY High Yield: Inattention is the core feature of both full and subsyndromal delirium; screening should prioritize attentional testing (e.g., Digit Span, months backward) over general orientation [100].

Prevention strategies focus on mitigating modifiable risk factors and utilizing targeted pharmacological prophylaxis in high-risk surgical settings. While non-pharmacological multicomponent interventions remain the standard of care, evidence supports specific pharmacological and environmental adjuncts to reduce incidence and improve clinical outcomes ^[116]^D5.

Primary Prevention and Prophylaxis

Pharmacological prophylaxis is indicated for specific high-risk populations, particularly elderly patients undergoing major surgery. Prophylactic low-dose (0.1 μg/kg per h) administered from ICU admission until the first postoperative morning significantly reduces delirium incidence from 23% to 9% (, 95%; NNT = 8) ^[23]^A1b. This regimen also reduces the risk of postoperative (10% vs 18%) and tachycardia (7% vs 14%) ^[23]^A1b.

Non-pharmacological interventions are effective for primary prevention by addressing environmental and physiological stressors ^[116]^D5:

Environmental Optimization: Maintaining day-night orientation, minimizing noise and light during rest, and clustering care activities ^[249]^A1c.
Sensory and Cognitive Support: Ensuring use of visual and hearing aids, promoting early mobility, and preventing dehydration or sleep deprivation ^[116]^D5.

Screening Instruments and Diagnostic Accuracy

Systematic screening is essential, as clinical intuition often fails to recognize acute fluctuations in attention ^[5]^A1a. The choice of instrument depends on the clinical setting and the patient's ability to verbalize.

Instrument	Setting	Performance (LR+ / LR-)	Administration Time
CAM	General Ward	9.6 / 0.16	5 minutes ^[5]^A1a
CAM-ICU	ICU / Ventilated	High sensitivity/specificity ^[6]^A1a	<5 minutes ^[163]^B2b
4AT	Rapid Screening	High sensitivity ^[116]^D5	<2 minutes
DRS-R-98	Severity/Research	>5.0 / <0.2	Variable ^[5]^A1a
BSEEG	Objective Monitoring	Correlates with severity ^[163]^B2b	Point-of-care EEG

The Confusion Assessment Method (CAM) is the most robustly supported bedside tool (LR+ 9.6, 95% CI 5.8-16.0) ^[5]^A1a. For patients in the ICU, the CAM-ICU is the standard for both verbal and mechanically ventilated patients ^[6]^A1a. Conversely, the (MMSE) is the least useful tool for identifying delirium (LR 1.6, 95% CI 1.2-2.0) ^[5]^A1a.

Risk Stratification and Early Intervention

Early identification of high-risk patients allows for targeted monitoring and preemptive intervention. In patients with advanced cancer, the pooled prevalence of delirium is 35.6%, necessitating routine screening in oncology units ^[250]^A1a.

Predictive Nomograms: In critically ill cancer patients, independent predictors include male gender, older age, elevated creatinine, and lower potassium ^[90]^B3b.
Pediatric Considerations: In children, delirium is a Tier 3 predictor for post-extubation dysphagia ^[141]^D5. Screening should be integrated into post-PICU follow-up at 3, 6, and 12 months to monitor for Paediatric Post-Intensive Care Syndrome (PICS-p) ^[248]^A1c.

Pearl: The CAM is the gold-standard bedside screening tool with a positive likelihood ratio of 9.6; do not rely on the MMSE, which has a negligible LR of 1.6 for delirium ^[5]^A1a.

Diagnostic Accuracy of Bedside Delirium Instruments

Instrument	Positive LR (95% CI)	Negative LR (95% CI)	Clinical Utility
CAM	9.6 (5.8-16.0)	0.16 (0.09-0.29)	Best supportive evidence; 5-min administration
MDAS	>5.0	<0.2	Effective for severity and diagnosis
DOSS	>5.0	<0.2	Nurse-led observation tool
MMSE (<24)	1.6 (1.2-2.0)	Not reported	Poor utility for delirium identification

References

[1]
Rogers JP, Chesney E, Oliver D et al.. “Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic.” The lancet. Psychiatry (2020). PMID: 32437679 ↗
L1SR_OBSCited in: Definition, Classification and Nomenclature, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Severity, Course Specifiers and Risk Stratification, Acute Management and Psychiatric Emergencies, Complications, Comorbidity and Iatrogenic Harm, Prognosis and Natural History
[2]
Hatta K, Kishi Y, Wada K et al.. “Preventive effects of ramelteon on delirium: a randomized placebo-controlled trial.” JAMA psychiatry (2014). PMID: 24554232 ↗
L1RCTCited in: Definition, Classification and Nomenclature, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Acute Management and Psychiatric Emergencies, History and Evolution of Treatment, Special Populations, Pregnancy and Perinatal Psychiatry
[3]
Walther S, Stegmayer K, Wilson JE et al.. “Structure and neural mechanisms of catatonia.” The lancet. Psychiatry (2019). PMID: 31196794 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Epidemiology, Etiology and Risk Factors, Clinical Presentation
[4]
D'Amico F, Turi S, Manazza M et al.. “Interventions to prevent postoperative neurocognitive complications: an umbrella review of meta-analyses of randomised controlled trials.” Anaesthesia (2025). PMID: 41243663 ↗
L1SR_MA_RCTCited in: Definition, Classification and Nomenclature
[5]
Wong CL, Holroyd-Leduc J, Simel DL et al.. “Does this patient have delirium?: value of bedside instruments.” JAMA (2010). PMID: 20716741 ↗
L1REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Prevention, Screening and Early Intervention
[6]
Miranda F, Gonzalez F, Plana MN et al.. “Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) for the diagnosis of delirium in adults in critical care settings.” The Cochrane database of systematic reviews (2023). PMID: 37987526 ↗
L1SR_OBSCited in: Definition, Classification and Nomenclature, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Acute Management and Psychiatric Emergencies, Special Populations, Pregnancy and Perinatal Psychiatry, Prevention, Screening and Early Intervention
[7]
Herling SF, Greve IE, Vasilevskis EE et al.. “Interventions for preventing intensive care unit delirium in adults.” The Cochrane database of systematic reviews (2018). PMID: 30484283 ↗
L1SR_OBSCited in: Definition, Classification and Nomenclature, Clinical Presentation, Acute Management and Psychiatric Emergencies, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Complications, Comorbidity and Iatrogenic Harm, Special Populations, Pregnancy and Perinatal Psychiatry
[8]
Burry L, Hutton B, Williamson DR et al.. “Pharmacological interventions for the treatment of delirium in critically ill adults.” The Cochrane database of systematic reviews (2019). PMID: 31479532 ↗
L1SR_OBSCited in: Definition, Classification and Nomenclature, Clinical Presentation, Acute Management and Psychiatric Emergencies, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Complications, Comorbidity and Iatrogenic Harm
[9]
Miller D, Lewis SR, Pritchard MW et al.. “Intravenous versus inhalational maintenance of anaesthesia for postoperative cognitive outcomes in elderly people undergoing non-cardiac surgery.” The Cochrane database of systematic reviews (2018). PMID: 30129968 ↗
L1SR_OBSCited in: Definition, Classification and Nomenclature, Acute Management and Psychiatric Emergencies, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Complications, Comorbidity and Iatrogenic Harm, Special Populations, Pregnancy and Perinatal Psychiatry
[10]
Candy B, Jackson KC, Jones L et al.. “Drug therapy for delirium in terminally ill adult patients.” The Cochrane database of systematic reviews (2012). PMID: 23152226 ↗
L1SR_OBSCited in: Definition, Classification and Nomenclature, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
[11]
Punjasawadwong Y, Chau-In W, Laopaiboon M et al.. “Processed electroencephalogram and evoked potential techniques for amelioration of postoperative delirium and cognitive dysfunction following non-cardiac and non-neurosurgical procedures in adults.” The Cochrane database of systematic reviews (2018). PMID: 29761891 ↗
L1SR_OBSCited in: Definition, Classification and Nomenclature, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out)
[12]
Dean RL, Marquardt T, Hurducas C et al.. “Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder.” The Cochrane database of systematic reviews (2021). PMID: 34623633 ↗
L1SR_OBSCited in: Definition, Classification and Nomenclature, Neurobiology and Pathophysiology, Prognosis and Natural History
[13]
Yu Y, Zhang K, Zhang L et al.. “Cerebral near-infrared spectroscopy (NIRS) for perioperative monitoring of brain oxygenation in children and adults.” The Cochrane database of systematic reviews (2018). PMID: 29341066 ↗
L1SR_OBSCited in: Definition, Classification and Nomenclature, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out)
[14]
Shetty RM, Bellini A, Wijayatilake DS et al.. “BIS monitoring versus clinical assessment for sedation in mechanically ventilated adults in the intensive care unit and its impact on clinical outcomes and resource utilization.” The Cochrane database of systematic reviews (2018). PMID: 29464690 ↗
L1SR_OBSCited in: Definition, Classification and Nomenclature, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Prognosis and Natural History
[15]
Zhang F, Liu C, Yang M et al.. “A meta-analysis on the factors of postoperative delirium in patients undergoing routine care in the recovery room.” Frontiers in medicine (2026). PMID: 41970402 ↗
L2SR_OBSCited in: Definition, Classification and Nomenclature
[16]
Ara L, Miled ZB, Boustani M et al.. “Machine learning and artificial intelligence for delirium prediction with Electronic Health Records (EHR): a scoping review.” BMC medical informatics and decision making (2026). PMID: 41699573 ↗
L5SR_OBSCited in: Definition, Classification and Nomenclature
[17]
Hao X, Zhang Z, Cai C et al.. “Effect of intraoperative dexmedetomidine on postoperative mental health in cardiac surgery: a randomized controlled trial.” International journal of surgery (London, England) (2025). PMID: 41376475 ↗
L1RCTCited in: Definition, Classification and Nomenclature
[18]
Wang B, Du W, Shen H et al.. “Risk prediction models for postoperative delirium in adult patients undergoing cardiac surgery: a systematic review and meta-analysis.” BMC cardiovascular disorders (2026). PMID: 42032510 ↗
L2SR_OBSCited in: Definition, Classification and Nomenclature, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), History and Evolution of Treatment, Prognosis and Natural History
[19]
Ren W, Zheng K, Song J et al.. “Effects of remimazolam and sevoflurane on postoperative delirium and early cognitive impairment in elderly patients after laparoscopic-assisted gastrointestinal surgery: a randomized clinical trial.” Frontiers in medicine (2026). PMID: 41939764 ↗
L1TRIAL_NONRANDOMCited in: Definition, Classification and Nomenclature
[20]
Hu Y, Tang W, Jiang X. “Prevalence and risk factors for postoperative delirium after hip fracture in the elderly: A systematic review and meta-analysis.” Medicine (2026). PMID: 41578567 ↗
L2SR_OBSCited in: Definition, Classification and Nomenclature
[21]
Bastos J, Freitas A, Gandra G et al.. “Psychiatric comorbidity in hospitalised burn patients: A Portuguese population-based observational retrospective study (2000-2015).” Burns : journal of the International Society for Burn Injuries (2026). PMID: 41830718 ↗
L3COHORTCited in: Definition, Classification and Nomenclature
[22]
Xiao F, Zhong Q, Liu H et al.. “Impact of circadian rhythm change on postoperative delirium in elderly patients undergoing lower extremity orthopedic surgery: a propensity score-matched prospective cohort study.” Frontiers in medicine (2026). PMID: 41756376 ↗
L2COHORTCited in: Definition, Classification and Nomenclature
[23]
Su X, Meng ZT, Wu XH et al.. “Dexmedetomidine for prevention of delirium in elderly patients after non-cardiac surgery: a randomised, double-blind, placebo-controlled trial.” Lancet (London, England) (2016). PMID: 27542303 ↗
L1RCTCited in: Neurobiology and Pathophysiology, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, History and Evolution of Treatment, Prognosis and Natural History, Special Populations, Pregnancy and Perinatal Psychiatry, Prevention, Screening and Early Intervention
[24]
van Eijk MM, Roes KC, Honing ML et al.. “Effect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients: a multicentre, double-blind, placebo-controlled randomised trial.” Lancet (London, England) (2010). PMID: 21056464 ↗
L1RCTCited in: Neurobiology and Pathophysiology, Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, History and Evolution of Treatment, Complications, Comorbidity and Iatrogenic Harm, Prognosis and Natural History, Special Populations, Pregnancy and Perinatal Psychiatry
[25]
Girard TD, Exline MC, Carson SS et al.. “Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.” The New England journal of medicine (2018). PMID: 30346242 ↗
L1RCTCited in: Neurobiology and Pathophysiology, Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Acute Management and Psychiatric Emergencies, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, History and Evolution of Treatment, Prognosis and Natural History, Special Populations, Pregnancy and Perinatal Psychiatry
[26]
Walsh TS, Parker RA, Aitken LM et al.. “Dexmedetomidine- or Clonidine-Based Sedation Compared With Propofol in Critically Ill Patients: The A2B Randomized Clinical Trial.” JAMA (2025). PMID: 40388916 ↗
L1RCTCited in: Neurobiology and Pathophysiology, History and Evolution of Treatment, Complications, Comorbidity and Iatrogenic Harm, Special Populations, Pregnancy and Perinatal Psychiatry
[27]
Riker RR, Shehabi Y, Bokesch PM et al.. “Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial.” JAMA (2009). PMID: 19188334 ↗
L1RCTCited in: Neurobiology and Pathophysiology, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification, History and Evolution of Treatment, Special Populations, Pregnancy and Perinatal Psychiatry
[28]
Inouye SK, Westendorp RG, Saczynski JS. “Delirium in elderly people.” Lancet (London, England) (2013). PMID: 23992774 ↗
L5REVIEW_NARRATIVECited in: Neurobiology and Pathophysiology, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Acute Management and Psychiatric Emergencies, History and Evolution of Treatment, Special Populations, Pregnancy and Perinatal Psychiatry
[29]
Choi SH, Lee H, Chung TS et al.. “Neural network functional connectivity during and after an episode of delirium.” The American journal of psychiatry (2012). PMID: 22549209 ↗
L3OTHERCited in: Neurobiology and Pathophysiology, Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification, Special Populations, Pregnancy and Perinatal Psychiatry
[30]
Siddiqi N, Harrison JK, Clegg A et al.. “Interventions for preventing delirium in hospitalised non-ICU patients.” The Cochrane database of systematic reviews (2016). PMID: 26967259 ↗
L1SR_OBSCited in: Neurobiology and Pathophysiology, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Severity, Course Specifiers and Risk Stratification, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
[31]
Overshott R, Karim S, Burns A. “Cholinesterase inhibitors for delirium.” The Cochrane database of systematic reviews (2008). PMID: 18254077 ↗
L1SR_OBSCited in: Neurobiology and Pathophysiology, Severity, Course Specifiers and Risk Stratification, Acute Management and Psychiatric Emergencies
[32]
Liu J, Wang LN. “Baclofen for alcohol withdrawal.” The Cochrane database of systematic reviews (2019). PMID: 31689723 ↗
L1SR_OBSCited in: Neurobiology and Pathophysiology
[33]
Yu A, Wu S, Zhang Z et al.. “Cholinesterase inhibitors for the treatment of delirium in non-ICU settings.” The Cochrane database of systematic reviews (2018). PMID: 29952000 ↗
L1SR_OBSCited in: Neurobiology and Pathophysiology, Severity, Course Specifiers and Risk Stratification, Prognosis and Natural History, Special Populations, Pregnancy and Perinatal Psychiatry
[34]
Gowing L, Ali R, White J. “Opioid antagonists with minimal sedation for opioid withdrawal.” The Cochrane database of systematic reviews (2006). PMID: 16437438 ↗
L1SR_OBSCited in: Neurobiology and Pathophysiology, Severity, Course Specifiers and Risk Stratification, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
[35]
Gowing L, Ali R, White JM. “Opioid antagonists with minimal sedation for opioid withdrawal.” The Cochrane database of systematic reviews (2017). PMID: 28553701 ↗
L1SR_OBSCited in: Neurobiology and Pathophysiology, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification
[36]
Gowing L, Ali R, White JM. “Opioid antagonists with minimal sedation for opioid withdrawal.” The Cochrane database of systematic reviews (2009). PMID: 19821290 ↗
L1SR_OBSCited in: Neurobiology and Pathophysiology, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
[37]
Chen K, Lu Z, Xin YC et al.. “Alpha-2 agonists for long-term sedation during mechanical ventilation in critically ill patients.” The Cochrane database of systematic reviews (2015). PMID: 25879090 ↗
L1SR_OBSCited in: Neurobiology and Pathophysiology
[38]
Britton A, Russell R. “WITHDRAWN: Multidisciplinary team interventions for delirium in patients with chronic cognitive impairment.” The Cochrane database of systematic reviews (2007). PMID: 17636635 ↗
L1SR_OBSCited in: Neurobiology and Pathophysiology, History and Evolution of Treatment, Prognosis and Natural History
[39]
Heffernan ÁB, Steinruecke M, Dempsey G et al.. “Role of glia in delirium: proposed mechanisms and translational implications.” Molecular psychiatry (2024). PMID: 39463449 ↗
L5REVIEW_NARRATIVECited in: Neurobiology and Pathophysiology, Clinical Presentation, Acute Management and Psychiatric Emergencies, Complications, Comorbidity and Iatrogenic Harm
[40]
Wang X, Yang Z, Tang T et al.. “From neuroinflammation to neuroprotection: a bibliometric analysis of anesthesia-associated postoperative cognitive dysfunction to guide clinical research (2000-2024).” Frontiers in medicine (2026). PMID: 42100263 ↗
L5SR_OBSCited in: Neurobiology and Pathophysiology, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), History and Evolution of Treatment
[41]
Adamis D, van Dalen JW, Eikelenboom P. “Depressive symptoms as a risk factor for postoperative delirium in older adults: A systematic review and meta-analysis.” Journal of affective disorders (2026). PMID: 41687974 ↗
L2SR_OBSCited in: Neurobiology and Pathophysiology
[42]
Iqbal M, Modi P, Sehgal K et al.. “Clinical Presentations and Treatment of Baclofen Toxicity and Withdrawal: A Systematic Review.” CNS drugs (2026). PMID: 41555041 ↗
L4SR_OBSCited in: Neurobiology and Pathophysiology
[43]
Singh S, Mathur R, Chakladar A et al.. “Effectiveness and safety of dual orexin receptor antagonists for the prevention of delirium: A systematic review with meta-analysis and trial sequential analysis.” General hospital psychiatry (2025). PMID: 41401488 ↗
L1SR_OBSCited in: Neurobiology and Pathophysiology
[44]
van Gool WA, van de Beek D, Eikelenboom P. “Systemic infection and delirium: when cytokines and acetylcholine collide.” Lancet (London, England) (2010). PMID: 20189029 ↗
L5OTHERCited in: Neurobiology and Pathophysiology, Epidemiology, Etiology and Risk Factors, Clinical Presentation, History and Evolution of Treatment, Special Populations, Pregnancy and Perinatal Psychiatry
[45]
Walsh TS, Parker RA, Aitken LM et al.. “Alpha2 agonists for sedation to produce better outcomes for adults with critical illness: a synopsis of the A2B RCT with cost-effectiveness and process evaluation.” Health technology assessment (Winchester, England) (2026). PMID: 42384077 ↗
L1RCTCited in: Neurobiology and Pathophysiology, Acute Management and Psychiatric Emergencies, History and Evolution of Treatment, Complications, Comorbidity and Iatrogenic Harm, Special Populations, Pregnancy and Perinatal Psychiatry
[46]
Walsh TS, Parker RA, Aitken LM et al.. “Relative and bedside nurse assessment of comfort and communication during propofol, dexmedetomidine, or clonidine-based sedation: pre-planned analysis within the A2B RCT.” Health technology assessment (Winchester, England) (2026). PMID: 41549569 ↗
L1RCTCited in: Neurobiology and Pathophysiology
[47]
Janssens U. “[Frailty in intensive care medicine].” Medizinische Klinik, Intensivmedizin und Notfallmedizin (2026). PMID: 41843101 ↗
L5SR_OBSCited in: Neurobiology and Pathophysiology
[48]
Shi W, Zhu S, Xia T et al.. “Effect of evening dexmedetomidine nasal spray on postoperative sleep disturbance in patients undergoing laparoscopic cholecystectomy: protocol for a multicentre, prospective, randomised, double-blind, controlled trial.” BMJ open (2026). PMID: 42086269 ↗
L5TRIAL_NONRANDOMCited in: Neurobiology and Pathophysiology
[49]
Shin HW, Choi YJ, You HS et al.. “Comparison of the effect of neostigmine and sugammadex on postoperative delirium in surgical patients: A systematic review and meta-analysis.” Medicine (2026). PMID: 41790674 ↗
L1SR_OBSCited in: Neurobiology and Pathophysiology
[50]
Yamada Y, Nakashima H, Nagae M et al.. “Anticholinergic burden on admission assessed by the Japanese Anticholinergic Risk Scale and incident in-hospital delirium in older adults: A multicenter prospective cohort study.” Archives of gerontology and geriatrics (2026). PMID: 42060954 ↗
L2COHORTCited in: Neurobiology and Pathophysiology, Severity, Course Specifiers and Risk Stratification, Risk and Safety Assessment, Capacity and Therapeutic Setting
[51]
Rahbek MT, Kildegaard H, Hallas J et al.. “Acetylcholinesterase inhibitors and the risk of delirium - a Danish nationwide register-based cohort study.” Alzheimer's research & therapy (2026). PMID: 42050692 ↗
L2COHORTCited in: Neurobiology and Pathophysiology
[52]
Gomes NV, Edgar-Whelan H, Beqiri E et al.. “PRECISION study: impact of personalised cardiac anaesthesia and cerebral autoregulation on neurological outcomes in patients undergoing cardiac surgery - protocol for an international, multicentre, prospective cohort study.” BMJ open (2026). PMID: 41857828 ↗
L2COHORTCited in: Neurobiology and Pathophysiology
[53]
Terada T, Hirayama T, Sadahiro R et al.. “Perioperative switching to lemborexant for prevention of delirium in older cancer patients with insomnia taking GABAA receptor agonists: a retrospective study.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2025). PMID: 41369783 ↗
L3COHORTCited in: Neurobiology and Pathophysiology
[54]
Wei P, Zhu T, Hashimoto K et al.. “Exploring the lung-brain axis in perioperative neurocognitive disorders: a potential therapeutic target.” Molecular psychiatry (2026). PMID: 41991715 ↗
L5OTHERCited in: Neurobiology and Pathophysiology, Complications, Comorbidity and Iatrogenic Harm
[55]
Shankar-Hari M, Benghanem S, Bourhy L et al.. “Current knowledge and challenges of sepsis-associated encephalopathy.” Intensive care medicine (2026). PMID: 42301312 ↗
L5REVIEW_NARRATIVECited in: Neurobiology and Pathophysiology
[56]
Kane JM, Detke HC, Naber D et al.. “Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia.” The American journal of psychiatry (2009). PMID: 20008947 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, History and Evolution of Treatment, Special Populations, Pregnancy and Perinatal Psychiatry
[57]
Wu YC, Tseng PT, Tu YK et al.. “Association of Delirium Response and Safety of Pharmacological Interventions for the Management and Prevention of Delirium: A Network Meta-analysis.” JAMA psychiatry (2019). PMID: 30810723 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Complications, Comorbidity and Iatrogenic Harm, Prognosis and Natural History
[58]
Taquet M, Geddes JR, Husain M et al.. “6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records.” The lancet. Psychiatry (2021). PMID: 33836148 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification, Risk and Safety Assessment, Capacity and Therapeutic Setting
[59]
Turan A, Duncan A, Leung S et al.. “Dexmedetomidine for reduction of atrial fibrillation and delirium after cardiac surgery (DECADE): a randomised placebo-controlled trial.” Lancet (London, England) (2020). PMID: 32682483 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, History and Evolution of Treatment, Prognosis and Natural History
[60]
Avidan MS, Maybrier HR, Abdallah AB et al.. “Intraoperative ketamine for prevention of postoperative delirium or pain after major surgery in older adults: an international, multicentre, double-blind, randomised clinical trial.” Lancet (London, England) (2017). PMID: 28576285 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, History and Evolution of Treatment, Complications, Comorbidity and Iatrogenic Harm, Prognosis and Natural History, Special Populations, Pregnancy and Perinatal Psychiatry
[61]
. “Perioperative covert stroke in patients undergoing non-cardiac surgery (NeuroVISION): a prospective cohort study.” Lancet (London, England) (2019). PMID: 31422895 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Acute Management and Psychiatric Emergencies, Special Populations, Pregnancy and Perinatal Psychiatry
[62]
Neuman MD, Feng R, Carson JL et al.. “Spinal Anesthesia or General Anesthesia for Hip Surgery in Older Adults.” The New England journal of medicine (2021). PMID: 34623788 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, History and Evolution of Treatment, Special Populations, Pregnancy and Perinatal Psychiatry
[63]
Kapadia SR, Makkar R, Leon M et al.. “Cerebral Embolic Protection during Transcatheter Aortic-Valve Replacement.” The New England journal of medicine (2022). PMID: 36121045 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Acute Management and Psychiatric Emergencies, History and Evolution of Treatment, Complications, Comorbidity and Iatrogenic Harm, Prognosis and Natural History
[64]
Meybohm P, Bein B, Brosteanu O et al.. “A Multicenter Trial of Remote Ischemic Preconditioning for Heart Surgery.” The New England journal of medicine (2015). PMID: 26436208 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Acute Management and Psychiatric Emergencies, History and Evolution of Treatment, Prognosis and Natural History, Special Populations, Pregnancy and Perinatal Psychiatry
[65]
Wood E, Albarqouni L, Tkachuk S et al.. “Will This Hospitalized Patient Develop Severe Alcohol Withdrawal Syndrome?: The Rational Clinical Examination Systematic Review.” JAMA (2018). PMID: 30167704 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Severity, Course Specifiers and Risk Stratification, Acute Management and Psychiatric Emergencies, Risk and Safety Assessment, Capacity and Therapeutic Setting, History and Evolution of Treatment, Complications, Comorbidity and Iatrogenic Harm
[66]
Li T, Li J, Yuan L et al.. “Effect of Regional vs General Anesthesia on Incidence of Postoperative Delirium in Older Patients Undergoing Hip Fracture Surgery: The RAGA Randomized Trial.” JAMA (2022). PMID: 34928310 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Severity, Course Specifiers and Risk Stratification, History and Evolution of Treatment, Complications, Comorbidity and Iatrogenic Harm, Special Populations, Pregnancy and Perinatal Psychiatry
[67]
Deschamps A, Ben Abdallah A, Jacobsohn E et al.. “Electroencephalography-Guided Anesthesia and Delirium in Older Adults After Cardiac Surgery: The ENGAGES-Canada Randomized Clinical Trial.” JAMA (2024). PMID: 38857019 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), History and Evolution of Treatment, Complications, Comorbidity and Iatrogenic Harm, Special Populations, Pregnancy and Perinatal Psychiatry
[68]
Wildes TS, Mickle AM, Ben Abdallah A et al.. “Effect of Electroencephalography-Guided Anesthetic Administration on Postoperative Delirium Among Older Adults Undergoing Major Surgery: The ENGAGES Randomized Clinical Trial.” JAMA (2019). PMID: 30721296 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), History and Evolution of Treatment, Complications, Comorbidity and Iatrogenic Harm, Special Populations, Pregnancy and Perinatal Psychiatry
[69]
Rosa RG, Falavigna M, da Silva DB et al.. “Effect of Flexible Family Visitation on Delirium Among Patients in the Intensive Care Unit: The ICU Visits Randomized Clinical Trial.” JAMA (2019). PMID: 31310297 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, History and Evolution of Treatment
[70]
Sonneville R, Couffignal C, Sigaud F et al.. “Restrictive vs Liberal Physical Restraint Strategies in Critically Ill Patients: The R2D2-ICU Randomized Clinical Trial.” JAMA (2026). PMID: 41841304 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification, Acute Management and Psychiatric Emergencies, History and Evolution of Treatment, Complications, Comorbidity and Iatrogenic Harm, Special Populations, Pregnancy and Perinatal Psychiatry
[71]
Subramaniam B, Shankar P, Shaefi S et al.. “Effect of Intravenous Acetaminophen vs Placebo Combined With Propofol or Dexmedetomidine on Postoperative Delirium Among Older Patients Following Cardiac Surgery: The DEXACET Randomized Clinical Trial.” JAMA (2019). PMID: 30778597 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, History and Evolution of Treatment, Special Populations, Pregnancy and Perinatal Psychiatry
[72]
Judd LL, Schettler PJ, Brown ES et al.. “Adverse consequences of glucocorticoid medication: psychological, cognitive, and behavioral effects.” The American journal of psychiatry (2014). PMID: 25272344 ↗
L4CASE_REPORTCited in: Epidemiology, Etiology and Risk Factors, History and Evolution of Treatment
[73]
Fardet L, Petersen I, Nazareth I. “Suicidal behavior and severe neuropsychiatric disorders following glucocorticoid therapy in primary care.” The American journal of psychiatry (2012). PMID: 22764363 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Severity, Course Specifiers and Risk Stratification, Risk and Safety Assessment, Capacity and Therapeutic Setting, History and Evolution of Treatment, Prognosis and Natural History
[74]
Burton JK, Craig LE, Yong SQ et al.. “Non-pharmacological interventions for preventing delirium in hospitalised non-ICU patients.” The Cochrane database of systematic reviews (2021). PMID: 34280303 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Severity, Course Specifiers and Risk Stratification, Acute Management and Psychiatric Emergencies, Complications, Comorbidity and Iatrogenic Harm, Special Populations, Pregnancy and Perinatal Psychiatry
[75]
Hu RF, Jiang XY, Chen J et al.. “Non-pharmacological interventions for sleep promotion in the intensive care unit.” The Cochrane database of systematic reviews (2015). PMID: 26439374 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Complications, Comorbidity and Iatrogenic Harm
[76]
Burton JK, Craig L, Yong SQ et al.. “Non-pharmacological interventions for preventing delirium in hospitalised non-ICU patients.” The Cochrane database of systematic reviews (2021). PMID: 34826144 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Severity, Course Specifiers and Risk Stratification, Acute Management and Psychiatric Emergencies, Complications, Comorbidity and Iatrogenic Harm
[77]
Kudchadkar SR, Berger J, Patel R et al.. “Non-pharmacological interventions for sleep promotion in hospitalized children.” The Cochrane database of systematic reviews (2022). PMID: 35703367 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Acute Management and Psychiatric Emergencies, Complications, Comorbidity and Iatrogenic Harm, Special Populations, Pregnancy and Perinatal Psychiatry
[78]
Lonergan E, Luxenberg J, Areosa Sastre A. “Benzodiazepines for delirium.” The Cochrane database of systematic reviews (2009). PMID: 19821364 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Acute Management and Psychiatric Emergencies, Complications, Comorbidity and Iatrogenic Harm
[79]
Lonergan E, Luxenberg J, Areosa Sastre A et al.. “Benzodiazepines for delirium.” The Cochrane database of systematic reviews (2009). PMID: 19160280 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Acute Management and Psychiatric Emergencies, Complications, Comorbidity and Iatrogenic Harm
[80]
Lonergan E, Britton AM, Luxenberg J et al.. “Antipsychotics for delirium.” The Cochrane database of systematic reviews (2007). PMID: 17443602 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Severity, Course Specifiers and Risk Stratification, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Complications, Comorbidity and Iatrogenic Harm
[81]
Hartley P, Keating JL, Jeffs KJ et al.. “Exercise for acutely hospitalised older medical patients.” The Cochrane database of systematic reviews (2022). PMID: 36355032 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Acute Management and Psychiatric Emergencies, Special Populations, Pregnancy and Perinatal Psychiatry
[82]
Woodhouse R, Burton JK, Rana N et al.. “Interventions for preventing delirium in older people in institutional long-term care.” The Cochrane database of systematic reviews (2019). PMID: 31012953 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Severity, Course Specifiers and Risk Stratification, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Special Populations, Pregnancy and Perinatal Psychiatry
[83]
Siddiqi N, Stockdale R, Britton AM et al.. “Interventions for preventing delirium in hospitalised patients.” The Cochrane database of systematic reviews (2007). PMID: 17443600 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors
[84]
Yuan Y, Wang S, Wang H et al.. “Effects of music therapy on delirium, clinical outcomes, and psychological and sleep outcomes in adult ICU patients: a systematic review and meta-analysis.” Frontiers in medicine (2026). PMID: 42460074 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Acute Management and Psychiatric Emergencies, Complications, Comorbidity and Iatrogenic Harm, Prevention, Screening and Early Intervention
[85]
Zhang H, Yan S, Shi Y et al.. “Incidence of delirium in hospitalized heart failure patients: a systematic review and meta-analysis.” Frontiers in cardiovascular medicine (2026). PMID: 42395889 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Prevention, Screening and Early Intervention
[86]
Kanno Y, Shinsato K, Kako J et al.. “Nonpharmacological interventions for preventing delirium in adult patients with cancer: a systematic review and meta-analysis.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2026). PMID: 42390613 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation
[87]
Othman MI, Nashwan AJ, Singh K et al.. “Unraveling the link: A systematic review and meta analysis of acute respiratory distress syndrome and delirium.” Respiratory medicine (2026). PMID: 42320602 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Acute Management and Psychiatric Emergencies
[88]
Yang CT, Wilkins JM, DiCesare E et al.. “Health Outcomes of Discontinuing Antipsychotics After Hospitalization in Older Adults.” JAMA psychiatry (2025). PMID: 40366701 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Acute Management and Psychiatric Emergencies, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Complications, Comorbidity and Iatrogenic Harm, Special Populations, Pregnancy and Perinatal Psychiatry
[89]
Marcantonio ER. “Delirium in Hospitalized Older Adults.” The New England journal of medicine (2017). PMID: 29020579 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Prognosis and Natural History, Special Populations, Pregnancy and Perinatal Psychiatry
[90]
Wang G, Chen L, Zhao M et al.. “A nomogram for predicting delirium in critically ill cancer patients: A retrospective cohort study.” European journal of oncology nursing : the official journal of European Oncology Nursing Society (2026). PMID: 42413165 ↗
L3COHORTCited in: Epidemiology, Etiology and Risk Factors, Prevention, Screening and Early Intervention
[91]
Lee SY, Shin KH, Kim J. “Comparative study of recovery characteristics between remimazolam anesthesia with flumazenil and desflurane anesthesia for closed reduction of nasal bone fracture: a randomized controlled trial.” Korean journal of anesthesiology (2026). PMID: 42411142 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Severity, Course Specifiers and Risk Stratification, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
[92]
Yang CT, Wilkins JM, Kesselheim AS et al.. “Clinical outcomes after antipsychotic discontinuation in nursing home residents with dementia: a nationwide cohort study.” Alzheimer's research & therapy (2026). PMID: 42410659 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Complications, Comorbidity and Iatrogenic Harm
[93]
Lin M, Xiang Y, Luo T et al.. “Nomogram for subsyndromal delirium after cardiac surgery with cardiopulmonary bypass: a retrospective cohort study.” Frontiers in medicine (2026). PMID: 42388482 ↗
L3COHORTCited in: Epidemiology, Etiology and Risk Factors
[94]
Haugen KG, Hansen CM, Jensen SS et al.. “Incidence of medical and surgical complications, and subsequent mortality, after hip fracture surgery : a nationwide cohort study from 2010 to 2021.” The bone & joint journal (2026). PMID: 42379576 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Complications, Comorbidity and Iatrogenic Harm, Special Populations, Pregnancy and Perinatal Psychiatry
[95]
Wongtangman K, Reddy Janga S, Azimaraghi O et al.. “Effect of the orexin receptor antagonist, suvorexant, on sleep architecture in the early postoperative period following cardiac surgery: a randomized controlled trial.” Critical care (London, England) (2026). PMID: 42337809 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors
[96]
Chen J, Haron Z, Makhdzir N et al.. “Subsyndromal Delirium in Elderly Critical Care Patients: A Meta-Analysis of Prevalence and Risk Factors.” Geriatrics & gerontology international (2026). PMID: 42452999 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, History and Evolution of Treatment
[97]
Park S, Park KT, Kang N et al.. “Systemic Inflammatory Indexes as Predictors of Delirium, Thromboembolic Events, and Mortality After Hip Fracture and Major Orthopedic Surgery: A Meta-Analysis.” Journal of Korean medical science (2026). PMID: 42444379 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Complications, Comorbidity and Iatrogenic Harm
[98]
Perälä J, Kuoppasalmi K, Pirkola S et al.. “Alcohol-induced psychotic disorder and delirium in the general population.” The British journal of psychiatry : the journal of mental science (2010). PMID: 20807964 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), History and Evolution of Treatment, Complications, Comorbidity and Iatrogenic Harm, Special Populations, Pregnancy and Perinatal Psychiatry
[99]
Meagher D, Adamis D, Trzepacz P et al.. “Features of subsyndromal and persistent delirium.” The British journal of psychiatry : the journal of mental science (2011). PMID: 22075650 ↗
L4OTHERCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification, Complications, Comorbidity and Iatrogenic Harm, Prognosis and Natural History, Special Populations, Pregnancy and Perinatal Psychiatry
[100]
Meagher D, O'Regan N, Ryan D et al.. “Frequency of delirium and subsyndromal delirium in an adult acute hospital population.” The British journal of psychiatry : the journal of mental science (2014). PMID: 25359923 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Acute Management and Psychiatric Emergencies, Special Populations, Pregnancy and Perinatal Psychiatry, Prevention, Screening and Early Intervention
[101]
Qian ET, Casey JD, Wright A et al.. “Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial.” JAMA (2023). PMID: 37837651 ↗
L1OTHERCited in: Epidemiology, Etiology and Risk Factors, Acute Management and Psychiatric Emergencies, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
[102]
Xie J, Strauss VY, Martinez-Laguna D et al.. “Association of Tramadol vs Codeine Prescription Dispensation With Mortality and Other Adverse Clinical Outcomes.” JAMA (2021). PMID: 34665205 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
[103]
Colbourne L, Harrison PJ. “Brain-penetrant calcium channel blockers are associated with a reduced incidence of neuropsychiatric disorders.” Molecular psychiatry (2022). PMID: 35618884 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, History and Evolution of Treatment
[104]
Kelly Graves O, Kang J, Li H et al.. “Whole-blood transcriptomic analysis reveals preoperative complement inhibitor deficiencies linked to postoperative delirium.” Molecular psychiatry (2025). PMID: 40419651 ↗
L3OTHERCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Acute Management and Psychiatric Emergencies, Special Populations, Pregnancy and Perinatal Psychiatry
[105]
Hansen N, Knopp CM, Esselmann H et al.. “Prediction of postoperative delirium after cardiac surgery by the interplay between preoperative plasma p-tau181 and IL-6 and heart-brain axis related factors: results from the prospective observational study FINDERI.” Molecular psychiatry (2025). PMID: 41429986 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Severity, Course Specifiers and Risk Stratification, Special Populations, Pregnancy and Perinatal Psychiatry
[106]
Friedman JI, Soleimani L, McGonigle DP et al.. “Pharmacological treatments of non-substance-withdrawal delirium: a systematic review of prospective trials.” The American journal of psychiatry (2014). PMID: 24362367 ↗
L1SR_OBSCited in: Clinical Presentation, Severity, Course Specifiers and Risk Stratification, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
[107]
Clancy U, Gilmartin D, Jochems ACC et al.. “Neuropsychiatric symptoms associated with cerebral small vessel disease: a systematic review and meta-analysis.” The lancet. Psychiatry (2021). PMID: 33539776 ↗
L1SR_OBSCited in: Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification, Acute Management and Psychiatric Emergencies, Prognosis and Natural History
[108]
Schweickert WD, Pohlman MC, Pohlman AS et al.. “Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial.” Lancet (London, England) (2009). PMID: 19446324 ↗
L1RCTCited in: Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), History and Evolution of Treatment, Complications, Comorbidity and Iatrogenic Harm, Prognosis and Natural History, Special Populations, Pregnancy and Perinatal Psychiatry
[109]
Olsen HT, Nedergaard HK, Strøm T et al.. “Nonsedation or Light Sedation in Critically Ill, Mechanically Ventilated Patients.” The New England journal of medicine (2020). PMID: 32068366 ↗
L1RCTCited in: Clinical Presentation, Severity, Course Specifiers and Risk Stratification, Acute Management and Psychiatric Emergencies, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, History and Evolution of Treatment, Complications, Comorbidity and Iatrogenic Harm, Special Populations, Pregnancy and Perinatal Psychiatry
[110]
Andersen-Ranberg NC, Poulsen LM, Perner A et al.. “Haloperidol for the Treatment of Delirium in ICU Patients.” The New England journal of medicine (2022). PMID: 36286254 ↗
L1RCTCited in: Clinical Presentation, Acute Management and Psychiatric Emergencies, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, History and Evolution of Treatment, Complications, Comorbidity and Iatrogenic Harm
[111]
Abley C, Dickinson C, Andrews Z et al.. “Training interventions to improve general hospital care for older people with cognitive impairment: systematic review.” The British journal of psychiatry : the journal of mental science (2019). PMID: 30784394 ↗
L5SR_OBSCited in: Clinical Presentation, Special Populations, Pregnancy and Perinatal Psychiatry
[112]
Pandharipande PP, Girard TD, Jackson JC et al.. “Long-term cognitive impairment after critical illness.” The New England journal of medicine (2013). PMID: 24088092 ↗
L2TRIAL_NONRANDOMCited in: Clinical Presentation, Special Populations, Pregnancy and Perinatal Psychiatry
[113]
Witlox J, Eurelings LS, de Jonghe JF et al.. “Delirium in elderly patients and the risk of postdischarge mortality, institutionalization, and dementia: a meta-analysis.” JAMA (2010). PMID: 20664045 ↗
L2SR_OBSCited in: Clinical Presentation, Severity, Course Specifiers and Risk Stratification, Complications, Comorbidity and Iatrogenic Harm, Special Populations, Pregnancy and Perinatal Psychiatry
[114]
de Oliveira LGAM, Squizzato FAT, da Silva Matos HS et al.. “Quetiapine Versus Haloperidol for the Treatment of Delirium in Hospitalized Adults: A Meta-Analysis of Randomized Controlled Trials with Trial Sequential Analysis.” General hospital psychiatry (2026). PMID: 42365709 ↗
L1SR_MA_RCTCited in: Clinical Presentation, Severity, Course Specifiers and Risk Stratification, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Complications, Comorbidity and Iatrogenic Harm
[115]
Chaves-Filho A, Medrado MF, Zamboni T et al.. “Effectiveness and safety of melatoninergic agonists in preventing delirium in the ICU: an updated dose‒response meta-analysis of randomized controlled trials.” Critical care (London, England) (2026). PMID: 42310686 ↗
L1SR_MA_RCTCited in: Clinical Presentation
[116]
Oh ES, Fong TG, Hshieh TT et al.. “Delirium in Older Persons: Advances in Diagnosis and Treatment.” JAMA (2017). PMID: 28973626 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification, Acute Management and Psychiatric Emergencies, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Prognosis and Natural History, Special Populations, Pregnancy and Perinatal Psychiatry, Prevention, Screening and Early Intervention
[117]
Arnsten AFT, Ishizawa Y, Xie Z. “Scientific rationale for the use of α2A-adrenoceptor agonists in treating neuroinflammatory cognitive disorders.” Molecular psychiatry (2023). PMID: 37029295 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[118]
Grebe M, Dichter MN, Dano R et al.. “Components and effects of psychosocial support interventions for relatives of patients with delirium in hospitals, systematic review.” BMC geriatrics (2026). PMID: 42271273 ↗
L5SR_OBSCited in: Clinical Presentation, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
[119]
Yang YW, Zhang Y, Qu TY et al.. “Perioperative neurofilament light chain and glial fibrillary acidic protein as biomarkers of postoperative delirium: a systematic review and meta-analysis.” BMC geriatrics (2026). PMID: 42237267 ↗
L2SR_OBSCited in: Clinical Presentation
[120]
Davis DH, Muniz-Terrera G, Keage HA et al.. “Association of Delirium With Cognitive Decline in Late Life: A Neuropathologic Study of 3 Population-Based Cohort Studies.” JAMA psychiatry (2017). PMID: 28114436 ↗
L2OTHERCited in: Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Prognosis and Natural History, Special Populations, Pregnancy and Perinatal Psychiatry
[121]
Saczynski JS, Marcantonio ER, Quach L et al.. “Cognitive trajectories after postoperative delirium.” The New England journal of medicine (2012). PMID: 22762316 ↗
L2OTHERCited in: Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Special Populations, Pregnancy and Perinatal Psychiatry
[122]
Kharatha M, Rezaie S, Talebi SS et al.. “Effect of head and facial massage combined with aromatherapy on sleep quality and delirium in patients with acute myocardial infarction: A randomized controlled trial.” Complementary therapies in medicine (2026). PMID: 42336252 ↗
L1RCTCited in: Clinical Presentation, Severity, Course Specifiers and Risk Stratification, Acute Management and Psychiatric Emergencies, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, History and Evolution of Treatment, Complications, Comorbidity and Iatrogenic Harm, Special Populations, Pregnancy and Perinatal Psychiatry
[123]
Otani K, Yamada K, Terada M et al.. “Diagnostic visibility and context-dependent referral patterns in consultation-liaison psychiatry: A ten-year retrospective study.” General hospital psychiatry (2026). PMID: 42235102 ↗
L4COHORTCited in: Clinical Presentation, Special Populations, Pregnancy and Perinatal Psychiatry
[124]
Matar DY, Lee JJ, Niederegger T et al.. “Dementia and postoperative outcomes in older adults: national estimates and mechanistic pathways from a US cohort study.” Age and ageing (2026). PMID: 42200480 ↗
L2COHORTCited in: Clinical Presentation, Special Populations, Pregnancy and Perinatal Psychiatry
[125]
Weidmann AE, Schintler JA, Stauffer R et al.. “Exploring the association between medication, patient-specific factors and delirium in hospitalised patients: a 10-year retrospective, population-based cohort study in Iceland.” BMJ open (2026). PMID: 42191189 ↗
L2COHORTCited in: Clinical Presentation, Special Populations, Pregnancy and Perinatal Psychiatry
[126]
Meagher DJ, Moran M, Raju B et al.. “Phenomenology of delirium. Assessment of 100 adult cases using standardised measures.” The British journal of psychiatry : the journal of mental science (2007). PMID: 17267930 ↗
L4OTHERCited in: Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification, Special Populations, Pregnancy and Perinatal Psychiatry
[127]
Zhou Z, Metten P, Yuan Q et al.. “Genetic and genomic signatures in ethanol withdrawal seizure-prone and seizure-resistant mice implicate genes involved in epilepsy and neuronal excitability.” Molecular psychiatry (2022). PMID: 36198764 ↗
L5OTHERCited in: Clinical Presentation, Severity, Course Specifiers and Risk Stratification
[128]
Borsini A, Merrick B, Edgeworth J et al.. “Neurogenesis is disrupted in human hippocampal progenitor cells upon exposure to serum samples from hospitalized COVID-19 patients with neurological symptoms.” Molecular psychiatry (2022). PMID: 36195636 ↗
L5OTHERCited in: Clinical Presentation, Acute Management and Psychiatric Emergencies, Special Populations, Pregnancy and Perinatal Psychiatry
[129]
Skelly DT, Griffin ÉW, Murray CL et al.. “Acute transient cognitive dysfunction and acute brain injury induced by systemic inflammation occur by dissociable IL-1-dependent mechanisms.” Molecular psychiatry (2018). PMID: 29875474 ↗
L5OTHERCited in: Clinical Presentation, Acute Management and Psychiatric Emergencies
[130]
Cursano S, Battaglia CR, Urrutia-Ruiz C et al.. “A CRHR1 antagonist prevents synaptic loss and memory deficits in a trauma-induced delirium-like syndrome.” Molecular psychiatry (2020). PMID: 32051550 ↗
L5OTHERCited in: Clinical Presentation
[131]
Shehabi Y, Howe BD, Bellomo R et al.. “Early Sedation with Dexmedetomidine in Critically Ill Patients.” The New England journal of medicine (2019). PMID: 31112380 ↗
L1RCTCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, History and Evolution of Treatment, Prognosis and Natural History, Special Populations, Pregnancy and Perinatal Psychiatry
[132]
Kawazoe Y, Miyamoto K, Morimoto T et al.. “Effect of Dexmedetomidine on Mortality and Ventilator-Free Days in Patients Requiring Mechanical Ventilation With Sepsis: A Randomized Clinical Trial.” JAMA (2017). PMID: 28322414 ↗
L1RCTCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), History and Evolution of Treatment, Complications, Comorbidity and Iatrogenic Harm, Prognosis and Natural History, Special Populations, Pregnancy and Perinatal Psychiatry
[133]
Gasnier M, Pinson P, Beeker N et al.. “Acute COVID-19 severity markers predict post-COVID new-onset psychiatric disorders: A 2-year cohort study of 34,489 patients.” Molecular psychiatry (2024). PMID: 39284906 ↗
L2COHORTCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification, Acute Management and Psychiatric Emergencies, History and Evolution of Treatment, Special Populations, Pregnancy and Perinatal Psychiatry
[134]
Gbreel MI, Badran AS, Hassan M et al.. “Cerebral Embolic Protection Devices (CEPDs) During Transcatheter Aortic Valve Implantation (TAVI): A Meta-Analysis of Randomized Controlled Trials.” Clinical cardiology (2026). PMID: 42021683 ↗
L1SR_MA_RCTCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Prognosis and Natural History
[135]
Schofield-Robinson OJ, Lewis SR, Smith AF et al.. “Follow-up services for improving long-term outcomes in intensive care unit (ICU) survivors.” The Cochrane database of systematic reviews (2018). PMID: 30388297 ↗
L1SR_OBSCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Complications, Comorbidity and Iatrogenic Harm, Prognosis and Natural History
[136]
Sarai M, Tejani AM, Chan AH et al.. “Magnesium for alcohol withdrawal.” The Cochrane database of systematic reviews (2013). PMID: 23740536 ↗
L1SR_OBSCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Acute Management and Psychiatric Emergencies, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
[137]
Eamer G, Taheri A, Chen SS et al.. “Comprehensive geriatric assessment for older people admitted to a surgical service.” The Cochrane database of systematic reviews (2018). PMID: 29385235 ↗
L1SR_OBSCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Prognosis and Natural History
[138]
Lewis SR, Macey R, Eardley WG et al.. “Internal fixation implants for intracapsular hip fractures in older adults.” The Cochrane database of systematic reviews (2021). PMID: 33687067 ↗
L1SR_OBSCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Prognosis and Natural History
[139]
Rozemeijer S, Dubois EA, de Grooth HJ et al.. “Early high-dose vitamin C for out-of-hospital cardiac arrest: the VITaCCA randomized clinical trial.” Intensive care medicine (2026). PMID: 42301311 ↗
L1RCTCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification, History and Evolution of Treatment, Special Populations, Pregnancy and Perinatal Psychiatry
[140]
Li S, Song J, Xiao X et al.. “Effect of Transcutaneous Auricular Vagus Nerve Stimulation on Postoperative Cognitive Dysfunction in Older Patients: A Randomized Controlled Clinical Trial.” Neuromodulation : journal of the International Neuromodulation Society (2026). PMID: 42104979 ↗
L1RCTCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), History and Evolution of Treatment, Prognosis and Natural History
[141]
Xue Y, Zhang B, Zhao X et al.. “Characteristics, predictors, and management of post-extubation dysphagia in critically Ill children: a scoping review.” Frontiers in pediatrics (2026). PMID: 42376024 ↗
L5SR_OBSCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Prevention, Screening and Early Intervention
[142]
Li N, Zhou Z, Yao T et al.. “Diagnostic Accuracy of Screening Tools for Delirium in Adults Receiving Care in Intensive Care Units: A Systematic Review and Network Meta-Analysis.” Nursing & health sciences (2026). PMID: 42077053 ↗
L1SR_OBSCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out)
[143]
Mehta S, Burry L, Cook D et al.. “Daily sedation interruption in mechanically ventilated critically ill patients cared for with a sedation protocol: a randomized controlled trial.” JAMA (2012). PMID: 23180503 ↗
L1OTHERCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Prognosis and Natural History
[144]
Song Y, Sun X, Mei L et al.. “Transcutaneous tibial nerve stimulation versus sham stimulation for the treatment of catheter-related bladder discomfort in patients undergoing transurethral resection of the prostate: a prospective, randomized, placebo-controlled, double-blind trial.” Trials (2026). PMID: 42050700 ↗
L1RCTCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), History and Evolution of Treatment
[145]
Mazhari Z, Manafi Anari A, Heidari-Beni F et al.. “The Effect of Foot Reflexology Massage on Delirium and Physiological Indicators in Children Admitted to Pediatric Intensive Care Unit: A Randomized Clinical Trial.” TheScientificWorldJournal (2026). PMID: 42037043 ↗
L1RCTCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), History and Evolution of Treatment
[146]
Xu Z, Lu J, Saeed S et al.. “Safety and efficacy of remimazolam sedation for ICU patients on invasive mechanical ventilation: A meta-analysis of randomized controlled trials.” European journal of pharmacology (2026). PMID: 42031055 ↗
L1SR_MA_RCTCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out)
[147]
Driessens H, Wijma AG, Jansen CJ et al.. “Prehabilitation is associated with a reduced incidence of postoperative delirium in patients undergoing pancreatoduodenectomy: a propensity score-matched cohort study.” HPB : the official journal of the International Hepato Pancreato Biliary Association (2026). PMID: 42115021 ↗
L3COHORTCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Prognosis and Natural History
[148]
Wu HL, Chen JT, Cata JP et al.. “Preoperative proprotein convertase subtilisin/kexin type 9 inhibitors versus statins and postoperative adverse events in hyperlipidemia: A nationwide, active-comparator cohort study.” Atherosclerosis (2026). PMID: 42048760 ↗
L2COHORTCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification, Risk and Safety Assessment, Capacity and Therapeutic Setting, Prognosis and Natural History
[149]
Takatani Y, Sato Y, Sugita N et al.. “Preventive effects of active Protocol-Based Pharmacotherapy Management for delirium in general wards of emergency department (aPBPM trial): study protocol for a single-center, randomized controlled trial {1a}.” Trials (2026). PMID: 42163281 ↗
L5TRIAL_NONRANDOMCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out)
[150]
Li Y, Zhang R, Li N et al.. “The impact of dexmedetomidine on postoperative delirium in obstructive sleep apnea patients (DPOD-OSA): study protocol for a prospective randomized controlled trial.” Trials (2026). PMID: 42144647 ↗
L5TRIAL_NONRANDOMCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out)
[151]
Yue J, Wang Q, Tang Q et al.. “Effect of ultrasound-guided interscalene brachial plexus block using liposome bupivacaine combined with continuous esketamine infusion on quality of recovery in patients undergoing arthroscopic rotator cuff repair: study protocol for a randomized controlled trial.” Trials (2026). PMID: 42121214 ↗
L5TRIAL_NONRANDOMCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out)
[152]
Reade MC, Eastwood GM, Bellomo R et al.. “Effect of Dexmedetomidine Added to Standard Care on Ventilator-Free Time in Patients With Agitated Delirium: A Randomized Clinical Trial.” JAMA (2016). PMID: 26975647 ↗
L1RCTCited in: Severity, Course Specifiers and Risk Stratification, Acute Management and Psychiatric Emergencies, Prognosis and Natural History
[153]
Hui D, Frisbee-Hume S, Wilson A et al.. “Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial.” JAMA (2017). PMID: 28975307 ↗
L1RCTCited in: Severity, Course Specifiers and Risk Stratification, Acute Management and Psychiatric Emergencies, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
[154]
Garegnani L, Ivaldi D, Burgos MA et al.. “Exercise therapy for the treatment of delirium in the intensive care unit.” The Cochrane database of systematic reviews (2025). PMID: 40792601 ↗
L1SR_OBSCited in: Severity, Course Specifiers and Risk Stratification
[155]
Burry L, Mehta S, Perreault MM et al.. “Antipsychotics for treatment of delirium in hospitalised non-ICU patients.” The Cochrane database of systematic reviews (2018). PMID: 29920656 ↗
L1SR_OBSCited in: Severity, Course Specifiers and Risk Stratification, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
[156]
Li Y, Ma J, Jin Y et al.. “Benzodiazepines for treatment of patients with delirium excluding those who are cared for in an intensive care unit.” The Cochrane database of systematic reviews (2020). PMID: 32108325 ↗
L1SR_OBSCited in: Severity, Course Specifiers and Risk Stratification, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
[157]
Kusudo K, Mashima Y, Yasuda H et al.. “Psychiatric Symptoms Associated with Corticosteroid Use: A Systematic Review and Meta-analysis.” CNS drugs (2026). PMID: 42365562 ↗
L3SR_OBSCited in: Severity, Course Specifiers and Risk Stratification, Acute Management and Psychiatric Emergencies
[158]
Skovhus K, Kristensen P, Sindberg DB et al.. “Preoperative Frailty Assessed by the Record-Based Multidimensional Prognostic Index Predicts 90-Day Days Alive and out of Hospital Following Radical Cystectomy for Bladder Cancer: A Retrospective Cohort Study.” Journal of clinical medicine (2026). PMID: 42278918 ↗
L3COHORTCited in: Severity, Course Specifiers and Risk Stratification
[159]
Stroda A, Larmann J, Icks A et al.. “Disability after non-cardiac surgery - patient-centred outcomes and resource utilisation after non-cardiac surgery (PACORUS): a prospective multicentre cohort study.” Anaesthesia (2026). PMID: 42274020 ↗
L2COHORTCited in: Severity, Course Specifiers and Risk Stratification
[160]
Jiang Y, Du J, Luo J. “The predictive value of nurse-led preoperative frailty assessment for postoperative delirium in liver transplant recipients: a retrospective cohort study.” BMC anesthesiology (2026). PMID: 42271219 ↗
L3COHORTCited in: Severity, Course Specifiers and Risk Stratification, Prevention, Screening and Early Intervention
[161]
Rossum du Chattel AMV, Laane DWPM, Aydin FB et al.. “Frailty as defined by the comprehensive geriatric assessment frailty index (CGA-FI) is associated with in-hospital complications and mortality in geriatric hip fracture patients, A retrospective cohort study.” Injury (2026). PMID: 42085909 ↗
L3COHORTCited in: Severity, Course Specifiers and Risk Stratification, Risk and Safety Assessment, Capacity and Therapeutic Setting
[162]
Wang S, Han Y, Fan K et al.. “Association between peripheral serotonin levels and postoperative delirium in older adults undergoing gastrointestinal surgery: a single-centre, prospective cohort study protocol.” BMJ open (2026). PMID: 42082253 ↗
L5COHORTCited in: Severity, Course Specifiers and Risk Stratification
[163]
Yamanashi T, Crutchley KJ, Wahba NE et al.. “Evaluation of point-of-care thumb-size bispectral electroencephalography device to quantify delirium severity and predict mortality.” The British journal of psychiatry : the journal of mental science (2021). PMID: 35049468 ↗
L2OTHERCited in: Severity, Course Specifiers and Risk Stratification, Complications, Comorbidity and Iatrogenic Harm, Prevention, Screening and Early Intervention
[164]
Oresanya LB, Lyons WL, Finlayson E. “Preoperative assessment of the older patient: a narrative review.” JAMA (2014). PMID: 24867014 ↗
L5REVIEW_NARRATIVECited in: Severity, Course Specifiers and Risk Stratification, Risk and Safety Assessment, Capacity and Therapeutic Setting
[165]
Greinacher A, Friesecke S, Abel P et al.. “Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial.” Lancet (London, England) (2011). PMID: 21890192 ↗
L4TRIAL_NONRANDOMCited in: Acute Management and Psychiatric Emergencies, Complications, Comorbidity and Iatrogenic Harm
[166]
Mack MJ, Acker MA, Gelijns AC et al.. “Effect of Cerebral Embolic Protection Devices on CNS Infarction in Surgical Aortic Valve Replacement: A Randomized Clinical Trial.” JAMA (2017). PMID: 28787505 ↗
L1RCTCited in: Acute Management and Psychiatric Emergencies, Complications, Comorbidity and Iatrogenic Harm, Prognosis and Natural History
[167]
Pandharipande PP, Pun BT, Herr DL et al.. “Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial.” JAMA (2007). PMID: 18073360 ↗
L1RCTCited in: Acute Management and Psychiatric Emergencies, Complications, Comorbidity and Iatrogenic Harm
[168]
Breitbart W, Alici Y. “Agitation and delirium at the end of life: "We couldn't manage him".” JAMA (2008). PMID: 19109118 ↗
L5CASE_REPORTCited in: Acute Management and Psychiatric Emergencies
[169]
Marcantonio ER. “Postoperative delirium: a 76-year-old woman with delirium following surgery.” JAMA (2012). PMID: 22669559 ↗
L5CASE_REPORTCited in: Acute Management and Psychiatric Emergencies, Complications, Comorbidity and Iatrogenic Harm
[170]
Kakde SP, Arora N, Kakde M et al.. “Delirium-directed interventions and long-term cognitive outcomes in critically ill adults: a systematic review of randomized clinical trials.” Frontiers in neurology (2026). PMID: 42293087 ↗
L1SR_OBSCited in: Acute Management and Psychiatric Emergencies
[171]
Neuman MD, Wirtalla C, Werner RM. “Association between skilled nursing facility quality indicators and hospital readmissions.” JAMA (2014). PMID: 25321909 ↗
L2OTHERCited in: Acute Management and Psychiatric Emergencies
[172]
Wu JN, Xu JH, Ge JY et al.. “The Impact of General Anesthetics on Postoperative Delirium: A Narrative Review Based on Clinical Randomized Controlled Trials from the Last Five Years.” Geriatrics (Basel, Switzerland) (2026). PMID: 42345745 ↗
L5RCTCited in: Acute Management and Psychiatric Emergencies
[173]
Francis T, Sriganesh K, Mishra RK et al.. “Comparison of Intraoperative Hypotension Outcomes With and Without Hypotension Prediction Index Tool in Patients Undergoing Brain Tumor Surgery: A Randomized Controlled Trial.” Journal of neurosurgical anesthesiology (2026). PMID: 42328958 ↗
L1RCTCited in: Acute Management and Psychiatric Emergencies
[174]
He S, Zeng J, Zhang Y et al.. “Dual orexin receptor antagonists for preventing delirium in hospitalized older adults: protocol for a randomized-trial systematic review and meta-analysis.” Systematic reviews (2026). PMID: 42437946 ↗
L5SR_OBSCited in: Acute Management and Psychiatric Emergencies
[175]
Cai X, Shen K, Xiong H et al.. “Perioperative interventions in preventing postoperative delirium following orthopaedic surgery in the elderly: a Bayesian network meta-analysis.” Journal of orthopaedic translation (2026). PMID: 42294468 ↗
L1SR_OBSCited in: Acute Management and Psychiatric Emergencies
[176]
Seong H, Jin S, Song YJ et al.. “Remimazolam-based anesthesia in sepsis patients: a retrospective cohort study of hemodynamic stability and postoperative outcomes.” Frontiers in medicine (2026). PMID: 42460071 ↗
L3COHORTCited in: Acute Management and Psychiatric Emergencies, Complications, Comorbidity and Iatrogenic Harm
[177]
Kodali MC, Chen H, Liao FF. “Temporal unsnarling of brain's acute neuroinflammatory transcriptional profiles reveals panendothelitis as the earliest event preceding microgliosis.” Molecular psychiatry (2020). PMID: 33293688 ↗
L5OTHERCited in: Acute Management and Psychiatric Emergencies
[178]
Gonçalves Dias A, Cainé L. “Deaths in custody: Physical restraint, excited delirium and medico-legal investigation - A systematic review.” Journal of forensic and legal medicine (2026). PMID: 42385387 ↗
L5SR_OBSCited in: Acute Management and Psychiatric Emergencies
[179]
van den Boogaard M, Slooter AJC, Brüggemann RJM et al.. “Effect of Haloperidol on Survival Among Critically Ill Adults With a High Risk of Delirium: The REDUCE Randomized Clinical Trial.” JAMA (2018). PMID: 29466591 ↗
L1RCTCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Complications, Comorbidity and Iatrogenic Harm
[180]
Dos Reis MAOM, de Assis EBT, Swamy HK et al.. “Efficacy of Dexmedetomidine in Preventing Postoperative Delirium in Patients Undergoing Brain Surgery: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Neurocritical care (2026). PMID: 42151722 ↗
L1SR_MA_RCTCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
[181]
Zhong L, Zhong R, Xie B et al.. “Ketamine/esketamine for preventing rebound pain after peripheral nerve block: a systematic review and meta-analysis of randomized controlled trials.” Minerva anestesiologica (2026). PMID: 41860056 ↗
L1SR_MA_RCTCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
[182]
Finucane AM, Jones L, Leurent B et al.. “Drug therapy for delirium in terminally ill adults.” The Cochrane database of systematic reviews (2020). PMID: 31960954 ↗
L1SR_OBSCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Prognosis and Natural History
[183]
Clegg A, Siddiqi N, Heaven A et al.. “Interventions for preventing delirium in older people in institutional long-term care.” The Cochrane database of systematic reviews (2014). PMID: 24488526 ↗
L1SR_OBSCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Special Populations, Pregnancy and Perinatal Psychiatry
[184]
Burry L, Rose L, McCullagh IJ et al.. “Daily sedation interruption versus no daily sedation interruption for critically ill adult patients requiring invasive mechanical ventilation.” The Cochrane database of systematic reviews (2014). PMID: 25005604 ↗
L1SR_OBSCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
[185]
Xu T, Yang W, Chen L et al.. “Efficacy and safety of ketamine in total hip arthroplasty: a systematic review.” Journal of orthopaedic surgery and research (2026). PMID: 42231375 ↗
L5SR_OBSCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
[186]
Tang X, Luo G, He Q et al.. “Effect of perioperative esketamine administration on the incidence of postoperative delirium: a systematic review and meta-analysis.” BMC anesthesiology (2026). PMID: 41923212 ↗
L1SR_OBSCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
[187]
Yang W, Zhou L, Xue Y et al.. “The effect of esketamine on emergence delirium or agitation in children after anesthesia-a systematic review and meta-analysis.” BMC anesthesiology (2026). PMID: 41840508 ↗
L1SR_OBSCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
[188]
Maust DT, Kim HM, Seyfried LS et al.. “Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm.” JAMA psychiatry (2015). PMID: 25786075 ↗
L2OTHERCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Complications, Comorbidity and Iatrogenic Harm, Special Populations, Pregnancy and Perinatal Psychiatry
[189]
Strøm T, Martinussen T, Toft P. “A protocol of no sedation for critically ill patients receiving mechanical ventilation: a randomised trial.” Lancet (London, England) (2010). PMID: 20116842 ↗
L1OTHERCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, History and Evolution of Treatment, Special Populations, Pregnancy and Perinatal Psychiatry
[190]
Sun Y, Chen Y, Zhuang W et al.. “Effects of Fospropofol on intraoperative hemodynamics in patients undergoing Supratentorial tumor resection: A randomized controlled trial.” Journal of clinical anesthesia (2026). PMID: 42176429 ↗
L1RCTCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, History and Evolution of Treatment, Special Populations, Pregnancy and Perinatal Psychiatry
[191]
Helmy MA, Mostafa MS, Saber AT et al.. “Preemptive noradrenaline infusion: a game-changer against post-induction hypotension in surgical sepsis: a randomized double blind trial.” BMC anesthesiology (2026). PMID: 41965525 ↗
L1RCTCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
[192]
Niu K, Li L, Wu X et al.. “Median effective dose (ED50) of esketamine combined with different doses of propofol for children to inhibit the response to gastroscope insertion: a prospective dose-response clinical study.” BMC anesthesiology (2026). PMID: 41928105 ↗
L1RCTCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
[193]
Yuan W, Liang X, Zhang R et al.. “Effect of Remimazolam or Propofol Combined With Esketamine on Anesthesia and Early Perioperative Neurocognitive Disorders in Patients Undergoing Thoracoscopic Partial Lung Resection: A Randomized Clinical Trial.” Clinical therapeutics (2026). PMID: 41862356 ↗
L1RCTCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
[194]
Song J, Tu Y, Chen Q et al.. “Efficacy of virtual reality interventions in reducing preoperative anxiety in pediatric patients undergoing general anesthesia: a systematic review and meta-analysis.” PeerJ (2026). PMID: 42038473 ↗
L1SR_OBSCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
[195]
Correa-Morales JE, Mantilla-Manosalva N, Iriarte-Aristizábal MF et al.. “Dehydration in the Dying Process: An Integrative Systematic Review of Physiological Mechanisms and Clinical Implications.” Journal of pain & palliative care pharmacotherapy (2026). PMID: 41964573 ↗
L5SR_OBSCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
[196]
Xu M, Zhu R, She YJ et al.. “Perioperative Ketamine and Esketamine for Enhanced Recovery After Surgery (ERAS): A Systematic Review.” Journal of investigative surgery : the official journal of the Academy of Surgical Research (2026). PMID: 41814842 ↗
L5SR_OBSCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
[197]
Lateiresh M, Altayf A, Qatza A et al.. “Efficacy and Safety of Dexmedetomidine-Esketamine Versus Dexmedetomidine Alone as Premedication for Pediatric Anesthesia Induction: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis.” Paediatric anaesthesia (2026). PMID: 41806259 ↗
L1SR_OBSCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
[198]
Tang M, Zhu M, Chen G et al.. “Study of remimazolam besylate for general anaesthesia and population pharmacokinetics-pharmacodynamics in elderly, hepatic or renal-insufficient patients: a protocol for a multicentre randomised controlled trial in China.” BMJ open (2026). PMID: 42129987 ↗
L5TRIAL_NONRANDOMCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies
[199]
Khan SH, Xu C, Wang S et al.. “Effect of Delirium on Physical Function in Noncardiac Thoracic Surgery Patients.” American journal of critical care : an official publication, American Association of Critical-Care Nurses (2020). PMID: 32114617 ↗
L2RCTCited in: Psychopharmacology Monitoring and Safety Surveillance
[200]
Saiz-Rodríguez M, Peña T, Lázaro L et al.. “Outpatient treatment of COVID-19 with steroids in the phase of mild pneumonia without the need for admission as an opportunity to modify the course of the disease: A structured summary of a randomised controlled trial.” Trials (2020). PMID: 32646502 ↗
L5RCTCited in: Psychopharmacology Monitoring and Safety Surveillance
[201]
Beach SR, Gross AF, Hartney KE et al.. “Intravenous haloperidol: A systematic review of side effects and recommendations for clinical use.” General hospital psychiatry (2020). PMID: 32979582 ↗
L1SR_OBSCited in: Psychopharmacology Monitoring and Safety Surveillance
[202]
Bateman RM, Sharpe MD, Jagger JE et al.. “36th International Symposium on Intensive Care and Emergency Medicine : Brussels, Belgium. 15-18 March 2016.” Critical care (London, England) (2016). PMID: 27885969 ↗
L5OTHERCited in: Psychopharmacology Monitoring and Safety Surveillance
[203]
Perez-Lloret S, Rascol O. “Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia.” Journal of neural transmission (Vienna, Austria : 1996) (2018). PMID: 29511826 ↗
L5REVIEW_NARRATIVECited in: Psychopharmacology Monitoring and Safety Surveillance
[204]
Meyer-Massetti C, Cheng CM, Sharpe BA et al.. “The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond?” Journal of hospital medicine (2010). PMID: 20394022 ↗
L5REVIEW_NARRATIVECited in: Psychopharmacology Monitoring and Safety Surveillance
[205]
Ogino S, Miyamoto S, Miyake N et al.. “Benefits and limits of anticholinergic use in schizophrenia: focusing on its effect on cognitive function.” Psychiatry and clinical neurosciences (2013). PMID: 24102938 ↗
L5REVIEW_NARRATIVECited in: Psychopharmacology Monitoring and Safety Surveillance
[206]
Berling I, Isbister GK. “Mirtazapine overdose is unlikely to cause major toxicity.” Clinical toxicology (Philadelphia, Pa.) (2013). PMID: 24228948 ↗
L4OTHERCited in: Psychopharmacology Monitoring and Safety Surveillance
[207]
Hsu TW, Hsu CW, Tseng PT et al.. “Adverse outcomes between VMAT2 and anticholinergics in tardive dyskinesia: A target trial emulation.” Psychiatry and clinical neurosciences (2026). PMID: 41947298 ↗
L3OTHERCited in: Psychopharmacology Monitoring and Safety Surveillance
[208]
Lee S, Khoujah D, Eagles D et al.. “GRADE-Based Clinical Practice Guidelines for Emergency Department Delirium Risk Stratification, Screening, and Brain Imaging in Older Patients With Suspected Delirium.” Academic emergency medicine : official journal of the Society for Academic Emergency Medicine (2025). PMID: 41146403 ↗
L1GUIDELINECited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
[209]
Chen WH, Ding L, Sha Y et al.. “Risk prediction models for delirium in ICU patients: a systematic review and critical appraisal.” BMC anesthesiology (2025). PMID: 41390628 ↗
L2SR_OBSCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
[210]
Das O, Tang LY, Oh ES et al.. “Machine learning models for predicting postoperative delirium in non-cardiac surgery patients - systematic review and meta-analysis.” GeroScience (2025). PMID: 41239112 ↗
L2SR_OBSCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
[211]
Tu Y, Zhu H, Zhang X et al.. “Machine Learning-Based prediction models for postoperative delirium: a systematic review and Meta-Analysis.” BMC psychiatry (2025). PMID: 41057784 ↗
L2SR_OBSCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
[212]
Juarez-Martinez EL, Araia A, Prasad D et al.. “Five-decade prevalence of delirium in pneumonia, risk factors and associated mortality: a systematic review and meta-analysis.” European respiratory review : an official journal of the European Respiratory Society (2025). PMID: 40962401 ↗
L2SR_OBSCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
[213]
Shahid S, Kasbati M, Adawi SO et al.. “Efficacy of Cerebral Embolic Protection Device in Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2025). PMID: 40910674 ↗
L1SR_OBSCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
[214]
Lammers-Lietz F, Akyuez L, Boraschi D et al.. “Prediction and risk evaluation of delirium after surgery in older patients: development and internal validation of an algorithm from the prospective BioCog cohort study.” British journal of anaesthesia (2026). PMID: 41850989 ↗
L2COHORTCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
[215]
Zhao S, Wang J, Zhang Y et al.. “The revised-risk analysis index predicts postoperative delirium in older patients undergoing abdominal surgery: a prospective observational cohort study.” Geriatric nursing (New York, N.Y.) (2026). PMID: 41763152 ↗
L2COHORTCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
[216]
Agathis AZ, Wu J, Divino CM. “The new modified four-factor functional frailty index (mFF-4) in colorectal surgery: A retrospective cohort study.” Surgery (2026). PMID: 41483626 ↗
L3COHORTCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
[217]
Webb KL, Pruter WW, Boyapati RB et al.. “Delirium optimization with volunteer engagement (DOVE): a retrospective study.” The Gerontologist (2025). PMID: 41212537 ↗
L3COHORTCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
[218]
Wu SJ, Sharma N, Bauch A et al.. “Predicting Postoperative Delirium in Older Patients Before Elective Surgery: Multicenter Retrospective Cohort Study.” JMIR aging (2025). PMID: 40828691 ↗
L3COHORTCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting
[219]
Mayo-Smith MF. “Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal.” JAMA (1997). PMID: 9214531 ↗
L1GUIDELINECited in: History and Evolution of Treatment
[220]
Breitbart W, Marotta R, Platt MM et al.. “A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients.” The American journal of psychiatry (1996). PMID: 8561204 ↗
L1RCTCited in: History and Evolution of Treatment
[221]
Whitlock RP, Devereaux PJ, Teoh KH et al.. “Methylprednisolone in patients undergoing cardiopulmonary bypass (SIRS): a randomised, double-blind, placebo-controlled trial.” Lancet (London, England) (2015). PMID: 26460660 ↗
L1RCTCited in: History and Evolution of Treatment, Complications, Comorbidity and Iatrogenic Harm, Special Populations, Pregnancy and Perinatal Psychiatry
[222]
Hughes CG, Mailloux PT, Devlin JW et al.. “Dexmedetomidine or Propofol for Sedation in Mechanically Ventilated Adults with Sepsis.” The New England journal of medicine (2021). PMID: 33528922 ↗
L1RCTCited in: History and Evolution of Treatment
[223]
Saitz R, Mayo-Smith MF, Roberts MS et al.. “Individualized treatment for alcohol withdrawal. A randomized double-blind controlled trial.” JAMA (1994). PMID: 8046805 ↗
L1RCTCited in: History and Evolution of Treatment
[224]
Berrios GE. “Delirium and confusion in the 19th century: a conceptual history.” The British journal of psychiatry : the journal of mental science (1981). PMID: 7037094 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[225]
Spitzer RL, First MB, Williams JB et al.. “Now is the time to retire the term "organic mental disorders".” The American journal of psychiatry (1992). PMID: 1734746 ↗
L5OTHERCited in: History and Evolution of Treatment
[226]
Zhang X, Li Y, Zhang L et al.. “Frailty and postoperative complications in elderly patients undergoing cardiac surgery: a systematic review and meta-analysis.” BMC geriatrics (2026). PMID: 42026505 ↗
L1SR_OBSCited in: History and Evolution of Treatment
[227]
Wadstein J, Skude G. “Does hypokalaemia precede delirium tremens?” Lancet (London, England) (1978). PMID: 79917 ↗
L2OTHERCited in: History and Evolution of Treatment
[228]
Sosnowski KJ, Ranse KL, Mitchell ML et al.. “Effects of the ABCDEF Bundle on Delirium, Function, and Quality of Life in Australian ICU Patients: A Pragmatic Randomized Controlled Trial.” Critical care medicine (2026). PMID: 42159452 ↗
L1RCTCited in: History and Evolution of Treatment
[229]
Bulbena A, Berrios GE. “Pseudodementia: facts and figures.” The British journal of psychiatry : the journal of mental science (1986). PMID: 3955324 ↗
L4OTHERCited in: History and Evolution of Treatment
[230]
Vansteene C, Dubertret C, Aubin HJ et al.. “Severe alcohol withdrawal symptoms and the risk of suicidal acts in patients treated for alcohol use disorder.” The British journal of psychiatry : the journal of mental science (2025). PMID: 40977395 ↗
L2OTHERCited in: History and Evolution of Treatment
[231]
Berrios GE. “Temporary urinary incontinence in the acute psychiatric patient without delirium or dementia.” The British journal of psychiatry : the journal of mental science (1986). PMID: 3779278 ↗
L2OTHERCited in: History and Evolution of Treatment
[232]
Lewis SR, Macey R, Parker MJ et al.. “Arthroplasties for hip fracture in adults.” The Cochrane database of systematic reviews (2022). PMID: 35156194 ↗
L1SR_OBSCited in: Complications, Comorbidity and Iatrogenic Harm, Special Populations, Pregnancy and Perinatal Psychiatry
[233]
Hu M, Ma Y. “Effects of intraoperative inhalational versus intravenous anesthesia on perioperative neurological outcomes and long-term prognosis in patients with moyamoya disease undergoing revascularization surgery: a systematic review and meta-analysis.” BMC anesthesiology (2026). PMID: 42420869 ↗
L1SR_OBSCited in: Complications, Comorbidity and Iatrogenic Harm, Prognosis and Natural History, Prevention, Screening and Early Intervention
[234]
Zhu A, Liu Y, Guan T et al.. “Data-driven subtypes of postoperative delirium in surgical ICU patients: a secondary analysis of a prospective cohort study.” Anaesthesia, critical care & pain medicine (2026). PMID: 42442477 ↗
L2COHORTCited in: Complications, Comorbidity and Iatrogenic Harm
[235]
Wang YM, Tian Y, Wang SY et al.. “Feasibility and safety of an analgesia-first strategy without hypnotic sedatives in adult patients admitted to the intensive care unit after neurosurgical craniotomy: a protocol for a single-arm, single-center exploratory prospective study.” Frontiers in medicine (2026). PMID: 42359072 ↗
L4COHORTCited in: Complications, Comorbidity and Iatrogenic Harm
[236]
Sato Y, Saito J, Kudo R et al.. “Intraoperative hypotension did not have an impact on the development of adverse outcomes after off-pump coronary artery bypass grafting: a retrospective study.” Journal of anesthesia (2026). PMID: 42363956 ↗
L3COHORTCited in: Complications, Comorbidity and Iatrogenic Harm
[237]
Sánchez A, Sawant-Uttekar P, Pribadi AN et al.. “Effectiveness of non-pharmacological and pharmacological interventions on delirium duration in older adults with delirium: a systematic review and meta-analysis of randomised controlled trials.” Age and ageing (2026). PMID: 41965252 ↗
L1SR_MA_RCTCited in: Prognosis and Natural History
[238]
Sánchez A, Sawant-Uttekar P, Heinen D et al.. “Effectiveness of non-pharmacological and pharmacological interventions in preventing delirium in older adults: a systematic review and meta-analysis of randomised controlled trials.” Age and ageing (2026). PMID: 41911321 ↗
L1SR_MA_RCTCited in: Prognosis and Natural History
[239]
Zheng H, Yin Z, Zhang Q. “The impact of sedation depth on the occurrence of delirium and prognosis in intensive care unit patients: a meta-analysis.” Frontiers in medicine (2026). PMID: 42158115 ↗
L1SR_OBSCited in: Prognosis and Natural History
[240]
Boules M, Bright M, Krepska A et al.. “Association of postoperative elevation of biomarkers of neural injury in blood with postoperative neurocognitive disorders in adults receiving general anaesthesia: a systematic review.” British journal of anaesthesia (2026). PMID: 42115061 ↗
L2SR_OBSCited in: Prognosis and Natural History
[241]
O'Sullivan R, Inouye SK, Meagher D. “Delirium and depression: inter-relationship and clinical overlap in elderly people.” The lancet. Psychiatry (2014). PMID: 26360863 ↗
L5REVIEW_NARRATIVECited in: Prognosis and Natural History
[242]
McGuire SS, Brown CS, Palmer AK et al.. “The Downstream Effects of Prehospital Opioid Dosing in Older Adults: A Retrospective Cohort Study.” Academic emergency medicine : official journal of the Society for Academic Emergency Medicine (2026). PMID: 42023551 ↗
L3COHORTCited in: Prognosis and Natural History
[243]
Zhao Y, Jiang J, Pu J et al.. “Association between the monocyte-to-lymphocyte ratio and 28-day all-cause mortality in sepsis-associated delirium patients: a retrospective study and machine learning.” BMC infectious diseases (2026). PMID: 41965559 ↗
L3COHORTCited in: Prognosis and Natural History
[244]
Yu Y, Guo H, Li Z et al.. “Frailty-related multiple health outcomes in older individuals: an umbrella review of systematic reviews and meta-analyses.” Age and ageing (2026). PMID: 42234808 ↗
L1SR_OBSCited in: Special Populations, Pregnancy and Perinatal Psychiatry
[245]
Al-Diwani A, Theorell J, Zghoul T et al.. “The distinctive psychopathology of NMDAR-antibody encephalitis compared with primary psychoses: an international, multicentre, retrospective phenotypic analysis.” The lancet. Psychiatry (2026). PMID: 41386901 ↗
L3OTHERCited in: Special Populations, Pregnancy and Perinatal Psychiatry
[246]
Chen M, Ren Y, Wu X et al.. “Impact of dexmedetomidine administration timing on postoperative delirium in elderly patients with lower limb fractures: a study protocol for a randomised controlled trial.” BMJ open (2026). PMID: 42366003 ↗
L1TRIAL_NONRANDOMCited in: Special Populations, Pregnancy and Perinatal Psychiatry
[247]
Wang JL, Ye CH, Teng ZF et al.. “Targeting complement C3/C3aR pathway restores rejuvenation factor PF4 and mitigates neurocognitive impairments in age-related perioperative neurocognitive disorders.” Molecular psychiatry (2025). PMID: 40659841 ↗
L5OTHERCited in: Special Populations, Pregnancy and Perinatal Psychiatry
[248]
Chareyre J, Pouletty M, Morin L et al.. “Diagnosis and management of Children with Post-Intensive Care Syndrome in Paediatrics: Clinical Practice Guidelines by the French National Authority for Health (HAS).” Annals of intensive care (2026). PMID: 42317609 ↗
L1GUIDELINECited in: Prevention, Screening and Early Intervention
[249]
Al-Jelaify M, Hasan G, Temsah MH et al.. “Adapting Evidence-Based Practice Guidelines for Sedation, Analgesia, Withdrawal, and Delirium Assessment and Management in Critically Ill Children.” Critical care research and practice (2026). PMID: 42294009 ↗
L1GUIDELINECited in: Prevention, Screening and Early Intervention
[250]
Jiang L, Zhang Z, Liu X et al.. “Prevalence of delirium among patients with advanced cancer: a systematic review and meta-analysis.” Frontiers in neurology (2026). PMID: 42211305 ↗
L1SR_OBSCited in: Prevention, Screening and Early Intervention
[251]
Hong J, Zhao C, Lin L. “Effect of Remimazolam on Postoperative Delirium in Surgical ICU Patients: A Single-Center Prospective Cohort Study.” Critical care research and practice (2026). PMID: 42328302 ↗
L2COHORTCited in: Prevention, Screening and Early Intervention